University of Tennessee Health Science Center

UTHSC Digital Commons
Theses and Dissertations (ETD)

College of Graduate Health Sciences

11-2020

Role of Cerebral Vasculature and Effect of Circulating Exosomes
in Propagation of Systemic Inflammatory Responses into the
Central Nervous System
Mahesh Chandra Kodali
University of Tennessee Health Science Center

Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Bacterial Infections and Mycoses Commons, Circulatory and Respiratory Physiology
Commons, Medical Cell Biology Commons, Medical Neurobiology Commons, and the Neurosciences
Commons

Recommended Citation
Kodali, Mahesh Chandra (https://orcid.org/0000-0001-6023-1060), "Role of Cerebral Vasculature and
Effect of Circulating Exosomes in Propagation of Systemic Inflammatory Responses into the Central
Nervous System" (2020). Theses and Dissertations (ETD). Paper 535. http://dx.doi.org/10.21007/
etd.cghs.2020.0522.

This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC
Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized
administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu.

Role of Cerebral Vasculature and Effect of Circulating Exosomes in Propagation
of Systemic Inflammatory Responses into the Central Nervous System
Abstract
Sepsis-associated encephalopathy (SAE) is an acutely progressing brain dysfunction induced by systemic
inflammation. The mechanism of initiation of neuroinflammation during SAE, which ultimately leads to
delirium and cognitive dysfunction, remains elusive. The goal of this project was to study the molecular
events of SAE to capture its onset and progression into the central nervous system (CNS), and further
identify the cellular players involved in mediating acute inflammatory signaling. Gene expression profiling
on the cerebral vessels isolated from the brains of the mice treated with peripheral lipopolysaccharide
(LPS) revealed that the cerebral vasculature responds within minutes to acute systemic inflammation by
upregulating the expression of immediate early response genes, followed by activation of the NF-κB
pathway. To identify the earliest responding cell type, fluorescence-activated cell sorting (FACS) was
utilized to sort the immunolabelled glial and vascular cells from the brains of the mice treated with LPS at
different time points and gene expression profiling was performed. Bioinformatic analysis of the
sequencing data followed by further validation revealed that the cerebral endothelial cells (CECs)
activation is the earliest event in the CNS and that they are the most likely source of proinflammatory
mediators that could further initiate glial cell activation. This is further followed by the activation of
apoptotic signaling in the CECs which is known to lead to blood brain barrier (BBB) disruption and allow
the peripheral cytokines to leak into the CNS, exacerbate the gliosis and result in neuroinflammatory
cascade. Together, these results model the sequential events during the advancement of systemic
inflammation into the CNS, and facilitate better understanding of the interplay between the vascular and
glial cells in initiating and driving acute neuroinflammation during SAE.
Systemic inflammation does lead to neuroinflammation, thereby linking the peripheral inflammatory
conditions to the CNS. However, the mechanisms through which systemic inflammation exerts its effect
on the CNS are poorly understood. Exosomes are small (30 to 100 nanometers) membrane bound
extracellular vesicles released by most of the mammalian cells. Exosomes play a vital role in cell to cell
communication. This includes regulation of inflammatory responses by shuttling mRNAs, miRNAs and
cytokines both locally and systemically to the neighboring as well as distant cells to further modulate
their transcriptional and/or translational states and affect the functional phenotype of those cells which
have taken up these exosomes. The role of circulating blood exosomes in mediating neuroinflammation
during systemic inflammation was thus studied. Serum derived exosomes from LPS-challenged mice
(SDEL) were freshly isolated from the sera of the mice which were earlier treated with LPS and used to
study SDEL effects on neuroinflammation. Exosomes isolated from the sera of the mice injected with
saline were used as control. In vitro studies showed that the SDEL upregulate pro-inflammatory cytokine
gene expression in the cell lines of microglia (BV2), astrocytes (C8-D1A) and cerebral microvascular
endothelial cells (Bend.3). To further study their effects in vivo, SDEL were then intravenously injected into
normal adult mice. The recipient mice that received SDEL exhibited elevated microglial activation.
Moreover, increased astrogliosis, and elevated CNS expression of pro-inflammatory cytokine mRNA were
observed in SDEL recipient mice. Additionally, SDEL injected directly into the cerebral ventricles resulted in
significant microgliosis as well as, astrogliosis. Together, these results demonstrate a novel role of
peripheral circulating exosomes in causing neuroinflammation during systemic inflammatory conditions.
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ABSTRACT

Sepsis-associated encephalopathy (SAE) is an acutely progressing brain dysfunction
induced by systemic inflammation. The mechanism of initiation of neuroinflammation
during SAE, which ultimately leads to delirium and cognitive dysfunction, remains
elusive. The goal of this project was to study the molecular events of SAE to capture its
onset and progression into the central nervous system (CNS), and further identify the
cellular players involved in mediating acute inflammatory signaling. Gene expression
profiling on the cerebral vessels isolated from the brains of the mice treated with
peripheral lipopolysaccharide (LPS) revealed that the cerebral vasculature responds
within minutes to acute systemic inflammation by upregulating the expression of
immediate early response genes, followed by activation of the NF-κB pathway. To
identify the earliest responding cell type, fluorescence-activated cell sorting (FACS) was
utilized to sort the immunolabelled glial and vascular cells from the brains of the mice
treated with LPS at different time points and gene expression profiling was performed.
Bioinformatic analysis of the sequencing data followed by further validation revealed that
the cerebral endothelial cells (CECs) activation is the earliest event in the CNS and that
they are the most likely source of proinflammatory mediators that could further initiate
glial cell activation. This is further followed by the activation of apoptotic signaling in
the CECs which is known to lead to blood brain barrier (BBB) disruption and allow the
peripheral cytokines to leak into the CNS, exacerbate the gliosis and result in
neuroinflammatory cascade. Together, these results model the sequential events during
the advancement of systemic inflammation into the CNS, and facilitate better
understanding of the interplay between the vascular and glial cells in initiating and
driving acute neuroinflammation during SAE.
Systemic inflammation does lead to neuroinflammation, thereby linking the
peripheral inflammatory conditions to the CNS. However, the mechanisms through which
systemic inflammation exerts its effect on the CNS are poorly understood. Exosomes are
small (30 to 100 nanometers) membrane bound extracellular vesicles released by most of
the mammalian cells. Exosomes play a vital role in cell to cell communication. This
includes regulation of inflammatory responses by shuttling mRNAs, miRNAs and
cytokines both locally and systemically to the neighboring as well as distant cells to
further modulate their transcriptional and/or translational states and affect the functional
phenotype of those cells which have taken up these exosomes. The role of circulating
blood exosomes in mediating neuroinflammation during systemic inflammation was thus
studied. Serum derived exosomes from LPS-challenged mice (SDEL) were freshly
isolated from the sera of the mice which were earlier treated with LPS and used to study
SDEL effects on neuroinflammation. Exosomes isolated from the sera of the mice
injected with saline were used as control. In vitro studies showed that the SDEL
upregulate pro-inflammatory cytokine gene expression in the cell lines of microglia
(BV2), astrocytes (C8-D1A) and cerebral microvascular endothelial cells (Bend.3). To
further study their effects in vivo, SDEL were then intravenously injected into normal
adult mice. The recipient mice that received SDEL exhibited elevated microglial
activation. Moreover, increased astrogliosis, and elevated CNS expression of pro-
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inflammatory cytokine mRNA were observed in SDEL recipient mice. Additionally,
SDEL injected directly into the cerebral ventricles resulted in significant microgliosis as
well as, astrogliosis. Together, these results demonstrate a novel role of peripheral
circulating exosomes in causing neuroinflammation during systemic inflammatory
conditions.

vi

TABLE OF CONTENTS
CHAPTER 1. INTRODUCTION .....................................................................................1
Sepsis ...............................................................................................................................1
Inflammatory Response ...................................................................................................1
Systemic Inflammation and the Brain .............................................................................1
Sepsis-associated Encephalopathy ...................................................................................2
Epidemiology ...............................................................................................................2
Pathophysiology ...........................................................................................................3
Neuroinflammation ......................................................................................................3
SAE results in long term depression-like symptoms ...................................................4
LPS Model of Neuroinflammation ..................................................................................4
Exosomes .........................................................................................................................5
Exosomal biogenesis ....................................................................................................6
Exosomes and cell-cell communication.......................................................................6
Rationale and Specific Aims............................................................................................7
Project 1 .......................................................................................................................7
Rationale ................................................................................................................. 7
Hypothesis............................................................................................................... 7
Project 2 .......................................................................................................................8
Rationale ................................................................................................................. 8
Hypothesis............................................................................................................... 8
CHAPTER 2. MATERIALS AND METHODS............................................................10
Animals ..........................................................................................................................10
Lipopolysaccharide (LPS) Treatment ............................................................................10
Isolation of Cerebral Vessels .........................................................................................10
Brain Single Cell Suspension ........................................................................................10
Immunolabelling ............................................................................................................11
Fluorescence-activated Cell Sorting (FACS) ................................................................11
Immunohistochemistry on the Isolated Cerebral Vessels ..............................................11
Standard Real Time Quantitative Polymerase Chain Reaction (RT-qPCR) on
Forebrain Tissue Samples ..............................................................................................12
Microfluidic RT-qPCR on Samples of Cerebral Vessels and Sorted Cells ...................12
RNA Sequencing on Cerebral vessels, Sorted Cerebral Endothelial Cells and
Microglia ........................................................................................................................16
RNA-seq Data Analysis .................................................................................................16
Data Availability ............................................................................................................17
Code Availability ...........................................................................................................17
Exosome Isolation, Quantification, Size and Zeta Potential Measurement ...................17
Transfusion of Serum Derived Exosomes from Donor to Recipient Mice....................17
Brain Section Immunohistochemistry ...........................................................................18
Digital Image Quantification .........................................................................................19
Western Blot Analysis ...................................................................................................19
Statistics .........................................................................................................................19
vii

CHAPTER 3. PROGRESSION OF MOLECULAR SEQUALAE IN THE
BRAIN DURING THE INITIATION OF SEPSIS-ASSOCIATED
ENCEPHALOPATHY FOLLOWING SYSTEMIC INFLAMMATION..................20
Introduction ....................................................................................................................20
Results ............................................................................................................................21
Cerebral vessels elicit proinflammatory responses during SAE ................................21
Acute systemic inflammation rapidly affects the cerebral vessels during the
initiation of SAE ........................................................................................................21
Cerebrovascular cells are affected during SAE .........................................................42
Temporal transcriptional profiling of CECs and microglia reveal individual cell
type specific gene expression kinetics during the initiation of SAE..........................42
Cerebral endothelial cells are the earliest sensors in the CNS to the peripheral
inflammation ..............................................................................................................61
Discussion ......................................................................................................................71
CHAPTER 4. ROLE OF PERIPHERAL CIRCULATING EXOSOMES IN
MEDIATING NEUROINFLAMMATION DURING SYSTEMIC
INFLAMMATORY CONDITIONS ..............................................................................76
Introduction ....................................................................................................................76
Results ............................................................................................................................77
LPS induces widespread microgliosis .......................................................................77
Characterization of the isolated exosomes .................................................................77
Isolated exosomes are not contaminated with endotoxin after precipitation from
serum ..........................................................................................................................81
Systemic inflammatory conditions increase exosome secretion as well as total
exosomal protein content ...........................................................................................81
Serum derived exosomes purified from LPS-challenged mice activate microglia,
astrocytes, and cerebral microvascular endothelial cells ...........................................84
Serum derived exosomes purified from LPS-challenged mice increase
proinflammatory gene expression in the brain...........................................................84
Intravenously administered serum-derived exosomes purified from LPSchallenged mice induce microglial and astrocytic activation in the CNS..................84
Intracerebroventricular infusion of serum-derived exosomes purified from
LPS-challenged mice induce microglial and astrocytic activation in the CNS .........91
Discussion ......................................................................................................................91
CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS ................................96
Dissection of Molecular Sequalae Temporally in the Brain During the Progression
of SAE Reveals That the Cerebral Endothelial Cell Activation Is the Earliest Event
and It Precedes Microglial Activation ...........................................................................96
Peripheral Circulating Exosomes Contribute to Neuroinflammation During
Systemic Inflammatory Conditions ...............................................................................97
LIST OF REFERENCES ................................................................................................99

viii

APPENDIX A. GENE EXPRESSION FOLDCHANGES AND STATISTICS OF
INDIVIDUAL PAIRWISE COMPARISONS FROM RNA-SEQ ANALYSIS .......108
VITA................................................................................................................................129

ix

LIST OF TABLES
Table 2-1.

List of RT-qPCR primers obtained from primer bank. .................................13

Table 2-2.

List of RT-qPCR primers from obtained from previously validated
protocols. ......................................................................................................15

Table A-1. Supplementary table related to Figure 3-9 listing pairwise comparison
statistics in LPS 15 minutes compared to PBS. .........................................108
Table A-2. Supplementary table related to Figure 3-9 listing pairwise comparison
statistics in LPS 30 minutes compared to PBS. .........................................109
Table A-3. Supplementary table related to Figure 3-9 listing pairwise comparison
statistics in LPS 4 hours compared to PBS. ...............................................110
Table A-4. Supplementary table related to Figure 3-10. ...............................................111
Table A-5. Supplementary table related to Figure 3-11. ...............................................112
Table A-6. Supplementary table related to Figure 3-13A. ............................................115
Table A-7. Supplementary table related to Figure 3-13B listing pairwise comparison
statistics in LPS 30 minutes compared to PBS. .........................................116
Table A-8. Supplementary table related to Figure 3-14A listing pairwise comparison
statistics in LPS 4 hours compared to PBS. ...............................................117
Table A-9. Supplementary table related to Figure 3-23 listing pairwise comparison
statistics in CECs LPS 30 minutes compared to CECs PBS. .....................118
Table A-10. Supplementary table related to Figure 3-23 listing pairwise comparison
statistics in CECs LPS 1 hour compared to CECs PBS. ............................119
Table A-11. Supplementary table related to Figure 3-23 listing pairwise comparison
statistics in microglia LPS 1 hour compared to microglia PBS… .............119
Table A-12. Supplementary table related to Figure 3-23 listing pairwise comparison
statistics in CECs LPS 2 hours compared to CECs PBS............................120
Table A-13. Supplementary table related to Figure 3-23 listing pairwise comparison
statistics in microglia LPS 2 hours compared to microglia PBS................121
Table A-14. Supplementary table related to Figure 3-24. ...............................................122
Table A-15. Supplementary table related to Figure 3-25A. ............................................123
x

Table A-16. Supplementary table related to Figure 3-25B listing pairwise comparison
statistics in microglia LPS 1 hour compared to microglia PBS… .............125
Table A-17. Supplementary table related to Figure 3-29. ...............................................126
Table A-18. Supplementary table related to supplementary Figure 3-30A listing
pairwise comparison statistics in CECs LPS 2 hours compared to CECs
PBS… .........................................................................................................127

xi

LIST OF FIGURES
Figure 1-1. Scheme depicting the overall aims of the study..............................................9
Figure 3-1. Expression of proinflammatory genes in the forebrain during systemic
inflammation. ...............................................................................................22
Figure 3-2. Expression changes of cell-type specific genes detected in the brain
following systemic inflammation. ................................................................23
Figure 3-3. Characterization of isolated cerebral vessels. ...............................................25
Figure 3-4. Expression of vascular cell markers in the isolated cerebral vessels. ...........26
Figure 3-5. Expression of proinflammatory genes in the isolated cerebral vessels
during sepsis-associated encephalopathy. ....................................................27
Figure 3-6. PCA plot of RNA-seq data from cerebral vessels. .......................................28
Figure 3-7. Scatter plot and correlation plot of RNA-seq data from cerebral vessels. ....29
Figure 3-8. MA plots showing the pairwise comparisons of RNA-seq data from
cerebral vessels. ............................................................................................32
Figure 3-9. Heatmap of immediate early genes expression in cerebral vessels. .............34
Figure 3-10. Heatmap of the genes showing inflammatory response in cerebral
vessels at 15 minutes post LPS treatment. ...................................................35
Figure 3-11. Heatmap of the genes showing inflammatory response in cerebral
vessels at 30 minutes post LPS treatment. ...................................................36
Figure 3-12. Gene ontology enrichment plots showing the pairwise comparisons of
RNA-seq data from cerebral vessels. ...........................................................37
Figure 3-13. Heatmaps of the genes related to regulation of vascular tone in cerebral
vessels at 15 minutes and 30 minutes post LPS treatment. ..........................38
Figure 3-14. Effects of systemic inflammation on endothelial barrier integrity in
cerebral vessels. ............................................................................................39
Figure 3-15. RT-qPCR confirmation of immediate early gene expression in cerebral
vessels...........................................................................................................40
Figure 3-16. Heatmaps from the RT-qPCR data on the cerebral vessels for genes
belonging to LPS response and NF-κB signaling. .......................................43

xii

Figure 3-17. FACS strategy for the simultaneous sorting of gliovascular cells from an
adult mouse brain. ........................................................................................45
Figure 3-18. Expression of proinflammatory genes in the sorted gliovascular cell
populations from mouse brain. .....................................................................46
Figure 3-19. Expression of cell-type specific markers in sorted gliovascular cell
populations from mouse brain. .....................................................................48
Figure 3-20. PCA plot and Scatter plots of the RNA-seq data from sorted microglia
and cerebral endothelial cells. ......................................................................50
Figure 3-21. Heatmap of cell-type specific marker genes in microglia and cerebral
endothelial cells. ...........................................................................................52
Figure 3-22. MA plots showing the pairwise comparisons between each timepoint
post LPS treatment in sorted microglia and cerebral endothelial cells. .......53
Figure 3-23. Heatmap of immediate early genes expression in microglia and cerebral
endothelial cells. ...........................................................................................55
Figure 3-24. Heatmap of the genes showing inflammatory response in microglia and
cerebral endothelial cells at 30 minutes post LPS treatment. .......................56
Figure 3-25. Heatmap of the genes showing inflammatory response in microglia and
cerebral endothelial cells at 1-hour post LPS treatment. ..............................57
Figure 3-26. Gene ontology enrichment plots showing the pairwise comparisons
between each timepoint post LPS treatment in sorted microglia and
cerebral endothelial cells. .............................................................................59
Figure 3-27. MA plots showing the pairwise comparisons between sorted cerebral
endothelial cells and microglia at each time point post LPS treatment. ......62
Figure 3-28. Gene ontology enrichment plots showing the pairwise comparisons
between sorted cerebral endothelial cells and microglia at each time
point post LPS treatment. .............................................................................64
Figure 3-29. Heatmap of the genes related to the regulation of vascular tone in
cerebral vessels at 1-hour post LPS treatment. ............................................66
Figure 3-30. Effects of systemic inflammation on endothelial barrier integrity in
sorted and microglia and cerebral endothelial cells. ....................................67
Figure 3-31. Cerebral endothelial cells are the earliest to respond to the peripheral
inflammation in the CNS..............................................................................69

xiii

Figure 3-32. Microglia and macrophage populations in the brain during systemic
inflammation. ...............................................................................................72
Figure 4-1. LPS induces widespread microgliosis. .........................................................78
Figure 4-2. Characterization of the isolated exosomes....................................................80
Figure 4-3. Isolated exosomes are not contaminated with endotoxin after
precipitation from serum. .............................................................................82
Figure 4-4. Scheme depicting the in experimental design for investigating the effects
of serum derived exosomes. .........................................................................85
Figure 4-5. Serum derived exosomes purified from LPS-challenged mice activate
microglia, astrocytes, and cerebral microvascular endothelial cells. ...........86
Figure 4-6. Serum derived exosomes purified from LPS-challenged mice increase
proinflammatory gene expression in the brain. ............................................88
Figure 4-7. Intravenous administration of serum-derived exosomes purified from
LPS-challenged mice induce microglial and astrocytic activation in the
CNS. .............................................................................................................89
Figure 4-8. Intracerebroventricular infusion of serum-derived exosomes purified
from LPS-challenged mice induce microglial and astrocytic activation
in the CNS. ...................................................................................................92

xiv

LIST OF ABBREVIATIONS

AD
AGEs
ALIX
AMS
BBB
BCSFB
BSA
CEC
CLRs
CNS
CP
CSF
CVOs
DAMPs
ESCRT
EVs
FBS
FCCS
FTD
GEO
GO
HBSS
HEPES
HMGB1
IACUC
IBA1
ICV
IEGs
IFC
IL
IDO
IV
KYN
KYNA
LAT-1
LBP
LFC
LPS
LRT
MAPK
MCP-1
MVBs
NCBI

Alzheimer’s disease
Advanced glycated end products
ALG-2 interacting protein X
Amyotrophic lateral sclerosis
Blood brain barrier
Blood cerebro-spinal fluid barrier
Bovine serum albumin
Cerebral endothelial cell
C-type lectin receptors
Central nervous system
Choroid plexus
Cerebro-spinal fluid
Circumventricular organs
Damage associated molecular patterns
Endosomal sorting complex required for transport
Extracellular vesicles
Fetal bovine serum
Flow Cytometry and Cell Sorting
Frontotemporal lobar dementia
Gene expression omnibus
Gene ontology
Hank's Balanced Salt Solution
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
High mobility group box 1
Institutional Animal Care and Use Committee
Ionized calcium binding adaptor molecule 1
Intracerebroventricular
Immediate early genes
Integrated Fluidic Circuit
Interleukin
Indoleamine-2,3 dioxygenase
Intravenous
Kynurenine
Kynurenic acid
Large amino acid transporter 1
LPS binding protein
Log fold change
Lipopolysaccharide
Likelihood ratio test
Mitogen-activated protein kinase
Monocyte chemoattractant protein 1
Multi-vesicular bodies
National Center for Biotechnology Information

xv

NF-κB
NLRs
NMDA
NOD
NSAIDs
PAMPs
PBS
PCA
PD
PE
PFA
PGE2
PRRs
QA
RIG-1
RLRs
RNA-seq
RT-qPCR
SAE
SDEL
SEM
SIRS
TLRs
TNF
TRP
TSG101
UC
UTHSC

Nuclear factor-κB
NOD like receptors
N-methyl D-aspartate
Nucleotide oligomerization domain
Non-steroidal anti-inflammatory drugs
Pathogen associated molecular patterns
Phosphate buffered saline
Principal component analysis
Parkinson’s disease
Paired end
Paraformaldehyde
Prostaglandin E 2
Pattern recognition receptors
Quinolinic acid
Retinoic acid inducible gene 1
RIG-1 like receptors
RNA Sequencing
Real Time Quantitative Polymerase Chain Reaction (RT-qPCR)
Sepsis-associated encephalopathy
Serum derived exosomes purified after LPS challenge
Standard error of the mean
Systemic inflammatory response syndrome
Toll like receptors
Tumor necrosis factor
Tryptophan
Tumor susceptibility gene 101
Ultracentrifugation
University of Tennessee Health Science Center

xvi

CHAPTER 1.

INTRODUCTION

Sepsis
Sepsis is a complex disorder that develops due to a dysregulated immune response to
infection and causes multiple organ failure [1]. It is one of the leading causes of inhospital death in the United States, and the estimated yearly financial burden is about
US$24 billion [2].

Inflammatory Response
Inflammatory response is triggered by specific molecules derived from pathogenic
microorganisms like bacteria or from injured tissues. These unique molecules are known
as associated molecular patterns, as they are linked to various triggering signals which
initiate inflammatory responses. Pathogen-associated molecular patterns (PAMPs) are the
exogenous molecules possessed in common by microorganisms, that are required for the
survival of those organisms but are not present in the mammalian cells [3]. Examples of
PAMPs include lipoproteins, glycoproteins, lipopolysaccharides and nucleic acids from
bacteria and fungi, nucleic acids from bacteria and viruses. Damage associated molecular
patterns (DAMPs) are the endogenous molecules released by damaged or stressed tissues.
Examples of DAMPs include mitochondrial and nuclear DNA, advanced glycosylated
end products (AGEs), high mobility group box 1 (HMGB1) and S100 proteins [4].
Mammalian cells have various cell-surface receptors for recognizing PAMPs or DAMPs
which are known as pattern-recognition receptors (PRRs). These PRRs play an
indispensable role in recognizing and binding to the conserved regions of PAMPs or
DAMPs and initiating an inflammatory response [4]. Pattern recognition receptors
include toll-like receptors (TLRs), C-type lectin receptors (CLRs), nucleotide-binding
oligomerization domain (NOD) like receptors (NLRs), retinoic-acid inducible gene 1
(RIG-1) like receptors (RLRs) and receptor for advanced glycated end products (RAGE)
[4]. Inflammatory cytokines are primarily responsible for the deleterious effects as they
circulate in the blood during systemic inflammation [5].

Systemic Inflammation and the Brain
Systemic inflammation occurring either acutely due to sepsis [6], chronically due to
metabolic syndromes [7] or underlying peripheral inflammatory conditions is known to
affect acute as well as chronic neuroinflammatory and neurodegenerative diseases [8].
Dementia is a worldwide risk affecting 50 million population currently and posing a
threat to affect 135 million people by the year 2050. Neuroinflammation is the most
common pathological feature in ageing associated neurodegenerative diseases including
Alzheimer’s disease (AD), Parkinson’s disease (PD), Frontotemporal Lobar dementia
(FTD) and Amyotrophic Lateral Sclerosis (AMS) [9]. More recently it has become
apparent that systemic inflammation has an important role in the progression of these
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diseases. Several epidemiological studies show that therapeutic use of non-steroidal antiinflammatory drugs (NSAIDs) in humans decrease neurodegenerative disease developing
risk [10, 11] and has a protective effect on the development of AD [12] and PD [13],
implying an underlying role of systemic inflammation in the pathology of
neurodegenerative diseases.
The mechanisms mediating the effects of systemic inflammation on the brain are well
studied in the past decade. The resulting signals during systemic inflammation were
found to reach the brain via humoral, neural, and cellular pathways. The neural pathway
includes cytokine signal transmission via direct activation of catecholaminergic circuits
and afferent nerve fibers such as vagus nerve in the peripheral sympathetic nervous
system. The humoral pathway includes the movement of cytokines through the less intact
and leaky areas of the BBB, choroid plexus epithelium lining and the circumventricular
organs (CVOs). This is followed by the activation of cells alongside the cerebral blood
vessel cells in the brain parenchyma, which subsequently release second messengers like
prostaglandins (PGE2) and nitric oxide (NO). The cellular pathway includes the
movement of peripheral immune cells into the brain after cytokine stimulation of
microglia (mainly via TNF alpha) to produce monocyte chemoattractant protein-1 (MCP1), which draws in activated monocytes and macrophages [14].

Sepsis-associated Encephalopathy
The central nervous system (CNS) is one of the first organs affected during sepsis and
the clinical manifestation is termed Sepsis-associated encephalopathy (SAE) [15]. Sepsis
affects the brain rapidly and causes SAE which leads to delirium and an altered cognitive
state known as sickness behavior [16]. Fever, behavioral changes, altered cognition and
neuroimmune changes are the characteristics of such sickness behavior during SAE [17].
SAE is an acutely progressing brain dysfunction that accompanies systemic inflammatory
response syndrome (SIRS) or sepsis induced systemic inflammation and is characterized
by the absence of direct CNS infection [18]. It is often associated with increased
mortality, and the recovered patients have chronic neurological dysfunction with
diminished long term cognitive performance including impaired memory, attention,
mental processing speed, and altered visual-spatial abilities [18, 19].

Epidemiology
SAE is the most common type of encephalopathy encountered among patients in the
intensive care unit (ICU) [19] and about 750,000 cases are reported annually in the united
states alone of which about 62% require rehospitalization [20]. The rate of SAE incidence
is about 50% of the total admitted patients to ICU. As there is no well-agreed upon
definition of SAE, there is some ambiguity and variation about its reports of incidence
across various studies [21]. About 20 to 40% of the patients admitted to intensive care
unit eventually progress to encephalopathy [21]. Notably, delirium is observed in 70% of
the elderly patients placed on mechanical ventilators. Age, underlying inflammatory
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conditions, metabolic syndromes, previous cognitive impairment, kidney and liver failure
and the severity of sepsis are the most common risk factors [22, 23]. About 70% of the
patients were found to have accompanying bacterial infection alongside altered
neurological status varying from lethargy to coma [22].

Pathophysiology
The underlying pathobiology of SAE is still not completely understood. Several
mechanisms have been proposed to explain the development of SAE [24]. The most
widely accepted hypothesis suggests that a combination of dysregulated immune
response, altered brain perfusion, and damaged BBB lead to CNS dysfunction during
SAE [20, 25, 26]. Septic conditions result in three distinct pathophysiological processes
which include neuroinflammation, ischemia and cellular metabolic stress [17]. Activation
of the microglia results in acute neuroinflammation. Ischemia results in macro and
microcirculatory dysfunction in the cerebral vasculature [25]. Both of these processes in
addition to systemic inflammatory factors induce metabolic stress. Oxidative stress and
mitochondrial dysfunction further affect the functioning of neurons [27].

Neuroinflammation
Neuroinflammation is a pathophysiological process in which the glial cells, i.e.
microglia and astrocytes, are activated to secrete inflammatory mediators, which leads to
CNS dysfunction. The precise mechanism by which the peripheral immune system
contributes to acute neuroinflammation is still unclear as most of the studies in this area
are primarily on chronic neuroinflammation, i.e., either originating inside the CNS and
driven by the CNS resident innate immune system as in Alzheimer’s disease, or
originating outside the CNS and driven by the peripheral adaptive immune system, as in
multiple sclerosis [9]. The pathophysiology of the above chronic neurodegenerative
diseases differs from that of acutely progressing neuroinflammation during SAE and
sickness behavior, which is initiated primarily due to the responses in the peripheral
innate immune system, that are propagated into the CNS after being earlier initiated or
triggered outside the CNS [28].
The CNS is considered as a site of ‘immune privilege’, implying that adaptive
immune responses originate in the periphery and propagate into the CNS [29]. The BBB,
the blood cerebro-spinal fluid (CSF) barrier (BCSFB), and the arachnoid barrier are the
three major barriers between the blood and the CNS [30]. The maintenance of
homeostasis in the CNS is firmly regulated and dependent on these three anatomical
barriers. The brain endothelial cells form the BBB, choroid plexus (CP) epithelial cells
form the BCSFB, and the arachnoid epithelium form the middle layer of meninges [31].
The immune cells forming the myeloid compartment in the CNS include the inner
resident macrophages, i.e. microglial cells and the outer CP macrophages and dendritic
cells, Kolmer’s epiplexus cells and meningeal and perivascular macrophages [29, 32].
The BCSFB consisting of CP cells is recognized as a brain “immune sensor” engaging in
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the communication between the peripheral immune system and the CNS [33]. CP is a
highly vascularized invagination of specialized secretory epithelial cells in the lateral,
third and fourth cerebral ventricles of the brain and functions in the secretion of CSF.
The only immune cell population in normal brain parenchyma are microglia, the
highly specialized CNS resident tissue macrophages [29] These originate from a yolk sac
progenitor that gives rise to monocytes or macrophages [34]. Microglia remain for the
entire lifespan, proliferate locally, and do not require further replenishment from the bone
marrow [35, 36]. Inside the CNS, microglia are restricted to immunosuppressive milieu
and are safeguarded from plasma proteins [37, 38]. The BBB is an important anatomical
barrier consisting of cerebrovascular endothelial cells and pericytes surrounded by
astrocyte end feet. This barrier primarily serves to regulate the transport of solutes across
the CNS from the periphery [30].

SAE results in long term depression-like symptoms
Long term depression resulting after recovery from SAE is also attributed to the
inflammatory cytokines which play a key role in inducing the kynurenine pathway in the
brain [16, 39-41]. Activation of the enzyme indoleamine-2,3 dioxygenase (IDO) causes
the conversion of tryptophan (TRP) to kynurenine (KYN) [42, 43]. Kynurenine is
transported into the brain via large neural amino acid transporter (LAT-1) and then
metabolized to kynurenic acid (KYNA) in neurons, astrocytes, and oligodendrocytes. In
microglia, and perivascular macrophages, kynurenine is metabolized into 3-hydroxy
kynurenine, anthranilic acid and finally quinolinic acid (QA). N-methyl D-aspartate
(NMDA)-glutamate receptor is an important target of the two neuroactive end products of
kynurenine metabolism [44-48]. LPS induced depression-like behavior is reversed by
blocking the kynurenine pathway via inhibiting IDO or by blocking the NMDA receptor
[40].

LPS Model of Neuroinflammation
Lipopolysaccharide (LPS) is the most extensively studied bacterial endotoxin [49].
LPS is a pathogen-associated molecular pattern, which can activate the innate immune
system. The lipid A component has a molecular weight of less than 2000 Da functions as
the primary immunostimulatory component of LPS [50]. LPS is derived from gram
negative bacterial cell wall and is used experimentally to induce acute as well as chronic
systemic inflammation in in-vivo and in-vitro models to mimic inflammation-associated
pathophysiological states [51-54]. LPS triggers the activation of TLR4 receptor which is
constitutively expressed in peripheral antigen presenting cells. Inflammatory cascade is
then triggered by the activation of Nuclear factor-κB (NF-κB) and mitogen-activated
protein kinase (MAPK) signaling pathways [55-58]. TLR4 receptor is also expressed in
the resident cells of the CNS including microglia and astrocytes and therefore triggers
CNS immune response by activating microglia and astrocytes [59].

4

LPS response is dependent on the age and genetic background of the mice strains
being tested as well as on the source and purity of LPS [60-62]. In addition, the dose and
dosage regimen, and the route of administration also have a profound effect on systemic
inflammation evoked by LPS treatment in the recipient mice [63, 64]. LPS induced
systemic inflammation further leads to neuroinflammation and causes neurodegeneration
[65]. The studies done using various LPS doses, dosage regimens, route of administration
including treatment duration and harvest time point as well as the different LPS sources
and its serotypes to induce neuroinflammation in various mice strains are exhaustively
summarized in recent reviews [66, 67]. The half-life of LPS is also dependent on the
mice strain being treated, with reports suggesting from a very small duration of 3-4
minutes [68] as well as up to 12 hours [69, 70]. Thus, there is a considerable ambiguity in
the literature, where LPS was used to induce systemic inflammation and
neuroinflammation. These differences are primarily due to the presence of many
confounding variables related to the biological properties of LPS, route of administration
as well as the strains of mice being used, which together affect the outcome, when LPS is
being used experimentally.
LPS causes disruptive anatomical changes and non-disruptive functional changes in
endothelial cells of the BBB [71]. LPS also affects the integrity of BCSFB as it disrupts
tight junctions between the epithelial cells partly mediated by the MMP associated
cleavage of collagen 1 in the CP epithelium [33]. LPS is also known to induce sickness
behavior and cognitive impairment in mice as demonstrated in Morris water maze test
and passive avoidance test. Alongside increased microglial activation and neuronal cell
loss were observed predominantly in the hippocampus of the fore brain region [72]. Also,
LPS treatment was found to decrease in the proliferation of neural stem cells, cause
chronic increase in depressive and anxiety like behaviors, accompanied by alteration in
neuroinflammatory and neural plasticity-associated factors [64].

Exosomes
Propagation of inflammatory signals across the whole body via immune cells requires
intercellular communication [73]. Cytokines, chemokines, and cell surface receptors play
a vital role in transferring such signals between immune cells. Recent studies reveal that
immune cells can also transfer inflammatory responses by secreting nano-sized lipid
packages called exosomes, which carry different biomolecules including proteins, lipids
and nucleic acids that could be taken up by the recipient cells [74-77]. Exosomes are
membrane-bound, nanosized, homogenous population of extracellular vesicles (EVs) that
are released by cells of different lineages under homeostatic as well as pathological
conditions. Earlier believed to be as ‘extracellular trash’, exosomes have recently
initiated enormous interest after the discovery of their role in mediating intercellular
communication by shuttling functional proteins, mRNA as well as microRNAs
(miRNAs) to recipient cells [78].
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Exosomal biogenesis
Exosomes range in size from 30 nm to 100 nm and are encapsulated by a lipid bilayer
[77, 79]. Exosomes are of endocytic origin derived from an endolysosomal pathway and
are formed within multi-vesicular bodies (MVBs) by inward budding during endosome
maturation [80]. Exosomes are then released by the cells into the extracellular
environment upon fusion of the MVBs with the plasma membrane. Exosomal cargo
sorting is governed by proteins linked with the endosomal sorting complex required for
transport (ESCRT), which include ALG-2 interacting protein X (ALIX) and tumor
susceptibility gene 101 (TSG101) which are the most commonly used exosomal marker
proteins [81, 82]. In addition, exosomes also contain several intraluminal and
transmembrane proteins including heat shock proteins (HSP70, HSP90) and tetraspanin
proteins (CD9, CD63, CD81) [83].

Exosomes and cell-cell communication
Exosomes mediate cell to cell communication after they initially attach or fuse with a
recipient cell membrane and are then internalized by the mechanism of endocytosis [84,
85]. Despite their obvious homogeneous size, exosomes mediate a broad spectrum of
effects on the recipient cells indicating that different types of cells surrounded by varying
physiological microenvironments, release different kinds of exosomes characterized by
heterogeneity in their molecular profile [81]. Exosomal miRNAs have recently received
increased attention as they can regulate the gene expression of the recipient cells in both
paracrine and/or endocrine manner, suggesting exosome mediated miRNA transfer could
be a novel mechanism of intercellular communication to regulate cellular function [86].
Accumulating evidence in many cells including immune cells suggests that exosomal
transferred miRNA repress target genes in the recipient cells [73]. Interestingly, miRNAs
can also act as signals for membrane receptor activation as they can function as ligands
for toll like receptors [87]. TLR activation results in NF-κB signaling, followed by
secretion of pro-inflammatory cytokines, suggesting additional role of miRNAs in
inflammation, possibly by a mechanism independent of the conventional role of posttranscriptional gene regulation [88]. Recently, circular RNAs are identified as a novel
class of RNAs which are generated by the mechanism of back splicing [89]. Circular
RNAs function in regulating the gene as well as the micro RNA expression [90].
Increasing studies indicate that these circular RNAs are enriched in exosomes derived
from mammalian cells [91]. Exosomal miRNAs are also involved in the inflammatory
responses and some of them like mir-155, a promoter of inflammatory responses and
mir-146a, a mediator of immune suppression are secreted into exosomes during the
activation of innate immune cells including dendritic cells [73]. In addition, this
exosomal miRNA is transferred between dendritic cells, B-cells, myeloid cells and Tcells and further regulate the inflammatory responses to lipopolysaccharide [73].
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Rationale and Specific Aims

Project 1
Rationale
Sepsis and its associated systemic inflammatory response syndrome cause acute
inflammatory effects in the CNS followed by cerebrovascular dysfunction and disruptive
anatomical changes in the BBB. This further leads to significant lifelong impairment of
cognitive function. The precise mechanism by which the peripheral immune system
contributes to acute neuroinflammation is still unclear as most of the studies in this area
are primarily on chronic neuroinflammation i.e. either originating inside the CNS driven
by the CNS resident innate immune system as in Alzheimer’s disease or originating
outside the CNS driven by the peripheral adaptive immune system as in multiple
sclerosis. The pathophysiology of the above chronic neurodegenerative diseases differs
from that of acutely progressing neuroinflammation during SAE and sickness behavior,
which is initiated primarily due to the responses in the peripheral innate immune system
triggered outside the CNS. The cellular and molecular mechanisms of early events
associated with such acute neuroinflammation are not completely characterized. Detailed
knowledge on the immediate molecular effects of acute peripheral inflammation on the
vasculature in the CNS are lacking and, moreover, the responses of the vascular cells in
the CNS are not much studied compared to that on microglia and astrocytes. To prevent
the SIRS/sepsis-associated BBB dysfunction and neuro-cognitive damages, it is essential
to know the precise order of events as well as the contribution and interplay of the
involved cell types. This further helps to develop the therapeutic strategies to target the
earlier events from progressing to the BBB disruption and acute neuroinflammation and
thus prevent long-lasting damage to the brain.
Hypothesis
Cerebral vasculature in the CNS is the earliest sensor of systemic inflammation, and it
rapidly responds by alteration of transcriptional responses primarily in the cerebral
endothelial cells.
Specific aim 1. Elucidate the effects of acute systemic inflammation on the cerebral
vasculature.
Specific aim 2. Identify the earliest affected CNS cell type/s that first respond to
systemic inflammation?
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Project 2
Rationale
Systemic inflammation leads to neuroinflammation, thereby linking the peripheral
inflammatory condition to the CNS. However, the mechanisms through which systemic
inflammation exerts its effect on the CNS are poorly understood. Exosomes are small (30
to 100nm) membrane bound extracellular vesicles released by most of the mammalian
cells. Accumulating studies reveal that they play a vital role in cell to cell
communication. This includes regulation of inflammatory responses by shuttling
mRNAs, miRNAs and cytokines both locally and systemically to the neighboring as well
as distant cells, modulating the transcriptional and/or translational states and further
affecting the functional phenotype of those cells which have up taken these exosomes.
Though the central nervous system is known to be isolated from the peripheral
microenvironment, during chronic inflammatory conditions, irrespective of anatomical
integrity of the CNS immune barriers, there could be a functional deficit ultimately
leading to the passage of circulating exosomes from periphery into the CNS and
subsequent inflammatory pathway stimulation in CNS. Exosomes, which are found to
mediate intercellular immune signals in the periphery, could also possibly play a role in
transmitting the same to the CNS, and thus, it is worthwhile to study the role of exosome
mediated peripheral and CNS communication in detail and learn their overall
contribution to neuroinflammation during systemic inflammation.
Hypothesis
During systemic inflammation, peripheral circulating blood exosomes upregulate
proinflammatory targets in the CNS and contribute to the development of
neuroinflammation.
Specific aim 3. Study the in-vitro and in-vivo effects of peripheral circulating
exosomes during systemic inflammation, on the CNS.
The scheme depicting the overall experimental design for the specific aims is
presented in (Figure 1-1).
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Figure 1-1.

Scheme depicting the overall aims of the study.

For aims 1 and 2, systemic inflammation was induced by a single intraperitoneal injection
of LPS, and the mice brains were dissected at various treatment time points followed by
isolation of cerebral vessels or gliovascular cells and further transcriptomic profiling
study. For aim 3, circulating exosomes were collected from the serum of the mice which
were earlier injected with either PBS or LPS, the isolated exosomes were then studied for
neuroinflammatory effects in vitro and in vivo.
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CHAPTER 2.

MATERIALS AND METHODS

Animals
C57BL/6J mice were obtained from Jackson Laboratories, housed and bred in well
ventilated cages under standard laboratory conditions on 12:12 hour light-dark cycle with
food and water ad libitum. Both male and female mice aged between eight to twelve
weeks were used unless otherwise mentioned. All animal experimental procedures were
conducted in accordance with the animal care standards of the National Institute of
Health and were approved by the Institutional Animal Care and Use Committee (IACUC)
of the University of Tennessee Health Science Center (UTHSC).

Lipopolysaccharide (LPS) Treatment
Mice were randomized into experimental groups and received a single intraperitoneal
injection of either endotoxin-free phosphate buffered saline (PBS) or LPS from E. coli
O55:B5(Sigma-Aldrich L2880) dissolved and diluted in endotoxin-free PBS (10 mg kg-1
body weight [92-95]). Mice were sacrificed at specific time points post injection.

Isolation of Cerebral Vessels
Cerebral vessels were isolated from the mice as described [96, 97] with slight
modifications. Briefly, mice were sacrificed, followed by intracardiac perfusion with icecold PBS and the brains were isolated rapidly on ice. Meninges were carefully removed,
and the forebrains were dissected and resuspended in 20 ml of ice-cold Hank's Balanced
Salt Solution (HBSS) with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES). The dissected forebrains were homogenized in a Dounce homogenizer (placed
on ice), by performing 20 strokes at a steady pace initially without twisting and followed
by five more strokes with twisting. Samples were then pelleted at 2000xg for 10 minutes
in a prechilled centrifuge at 4°C. Supernatant was discarded followed by the addition of
20 ml of 18% dextran in HBSS with 10 mM HEPES. Pellet was then resuspended
followed by centrifugation at 2800xg for 30 minutes at 4°C. Supernatant was discarded,
and the pellet was finally resuspended in 5 ml of 1% BSA in HBSS, followed by
filtration through a 20 µm Nylon mesh. The retained fraction on the top of the mesh was
then carefully resuspended in 50 ml of HBSS containing 1% BSA and centrifuged at
2000xg for 10 minutes to yield the cerebral vessels.

Brain Single Cell Suspension
Single cell suspension of the brain was prepared by following the protocol described
[98]. Briefly, dissected whole forebrains free of meninges were cut into small pieces, that
were resuspended in 2.5 ml of HBSS containing 50 units of activated papain
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(Worthington, LK003178) and incubated at 37°C for 30 minutes. Prechilled HBSS with 2
mM EDTA and 2% fetal bovine serum (FBS) was added to halt the digestion, and the
cells were centrifuged at 300xg for 10 minutes at 4°C. The cells were then gently
triturated with a glass Pasteur pipette, followed by passage through a 70 µm filter
(Miltenyi, 13098462). The filtered cells were centrifuged at 300xg for 10 minutes at 4°C
and resuspended in 12 ml of 22% isotonic Percoll plus (Millipore Sigma, E0414-250ML)
in 1× HBSS at 4°C and centrifuged with low brake at 560xg at 4°C for 20 minutes. The
top myelin debris was then carefully discarded, and the cells were washed with HBSS
containing 2% FBS and then finally resuspended in HBSS. Resuspended cells were
stained with Live/Dead Fixable Blue Dead Cell stain (Thermo Fisher, L23105) and 1:100
diluted mouse CD16-CD32 Pure MAB 2.4G2 Fc Block (BD Biosciences, 553141) for 10
minutes in 200 ml of HBSS containing 2% FBS.

Immunolabelling
The cells were stained by addition of the following antibodies: 1:1000 BV421 Rat
Anti-Mouse CD45 Clone 30-F11 (BD Biosciences, 563890), 1:200 PE Rat Anti-Mouse
CD13 Clone R3-242 (BD Biosciences, 558745), 1:50 CD31 Rat Anti-Mouse FITC clone
MEC 13.3 (BD Biosciences, 553372), 1:200 Anti-O4-APC clone REA 576 (Miltenyi,
130-119-897), 1:1000 Alexa Fluor® 700 Rat anti-CD11b (BD Biosciences, 557960),
1:200 Anti-ACSA-2-PE-Vio615 (Miltenyi, 130-116-146) or 1:200 Anti-ACSA-2-APC
(Miltenyi, 130-116-245 only used in the initial sorting experiment, where anti-O4 was not
included). The cells with antibodies were then incubated on ice in the dark for 10
minutes, and then washed three times with HBSS containing 2% FBS. Finally, the cells
were resuspended in HBSS containing 2% FBS, 1:100 RNase free DNase (Qiagen,
79254) and 1:500 RNasein plus RNase inhibitor (Promega, N2611).

Fluorescence-activated Cell Sorting (FACS)
Cell sorting was performed using a BD Aria II cell sorter using the 100-micron nozzle.
Cells were sorted at 4°C and collected directly into Buffer RLT-Plus (Qiagen, 1053393)
containing 1:100 β-mercaptoethanol (Millipore Sigma, 444203-250ML). Appropriate
single colored controls and fluorescence minus one controls (FMOs) were included, and
gating and sorting was performed by the UTHSC Flow Cytometry and Cell Sorting
(FCCS) core. facility

Immunohistochemistry on the Isolated Cerebral Vessels
Isolated cerebral vessels were incubated in 4% formaldehyde for 20 minutes, washed
with PBS and resuspended in 400 ml of PBS. 50 µl of this suspension was plated on
Superfrost microscope slides (Fisher Scientific, 12-550-123) and air dried for 30 minutes,
to let the PBS evaporate and allow the vessels to mount onto the slide surface. The
mounted vessel fractions were then washed two times with PBS, followed by
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permeabilization and blocking with 5% bovine serum albumin (BSA) and 1% NP-40 in
PBS for 1 hour, stained with primary antibodies 1:100 anti-rabbit GLUT1 (PA1-46152,
Invitrogen) or 1:100 anti-mouse GLUT1 (ab40084, Abcam), anti-rabbit 1:100 COL-IV
(MN120-6586, Novus), 1:100 anti-mouse CD13 (M101-3, MBL International), 1:50 antimouse CD31 (BD Biosciences, 553372) and corresponding secondary antibodies, and
imaged using Olympus F1000 confocal fluorescence microscope.

Standard Real Time Quantitative Polymerase Chain Reaction (RT-qPCR) on
Forebrain Tissue Samples
Total RNA was extracted using the Trizol method and cDNA synthesis was performed
using the SuperScript™ IV VILO™ Master Mix with ezDNase™ Enzyme (Invitrogen,
11766050) according to the manufacturer’s protocols. All primer sequences were
obtained from the primer bank [99-101] (Table 2-1) or from previously published and
validated protocols [102, 103] (Table 2-2). RT-qPCR reactions were performed using 2X
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, 1725271) on an Eppendorf
Mastercycler Realplex2.

Microfluidic RT-qPCR on Samples of Cerebral Vessels and Sorted Cells
Total RNA was extracted from cerebral vessels or sorted cells using the RNeasy Plus
micro kit (Qiagen, 74034) and cDNA synthesis was performed as described above. RTqPCR was performed as per the protocol described [102]. Briefly, 1.25 μl of each cDNA
sample was pre-amplified using 2.5 μl of 2X Taqman pre-amplification master mix
(Applied Biosystems, 4391128) and 1.25 μl of the primer pool (200 nm final conc of the
primer pool). Pre-amplification was performed using 10 minutes 95°C denaturation step
and 14 cycles of 15 seconds at 95°C and 4 minutes at 60°C. The reaction products were
then cleaned up to remove unincorporated primers by using Exonuclease I treatment as
per the protocol in the Appendix C from the Fluidigm Biomark RT-PCR user guide
(Fluidigm PN 68000088 N1). Reaction products were diluted 1:10 in DNA resuspension
buffer (Teknova, T0221). Then 5 μl from a sample mix containing pre-amplified cDNA
and amplification master mix of 20X SsoFast EvaGreen Supermix with Low ROX (BioRad, 1725211) was loaded into each sample inlet of either a 48.48 or a 96.96 Dynamic
Array Integrated Fluidic Circuit (IFC) for gene expression (Fluidigm, BMK-M48.48/BMK-M-96.96). 5 μl from an assay mix containing DNA-assay loading reagent,
and forward and reverse primers (10 μm final conc) was loaded into each detector inlet.
The chip was then placed in either the IFC Controller MX for the 48.48 Dynamic array
IFC or IFC controller HX for the 96.96 Dynamic array IFC for loading and mixing. After
loading, the chip was processed in the BioMark RealTime PCR System (Fluidigm) using
a cycling program of 60 seconds at 95°C followed by 40 cycles of 96°C for 5 seconds,
60°C for 30 seconds and 72°C for 30 seconds. After completion of the RT-qPCR run, a
melting curve of amplified products was determined. RT-qPCR data was normalized
using the geometric mean of three reference genes Actb, Gapdh and Rplp0, analyzed
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Table 2-1.
Gene

List of RT-qPCR primers obtained from primer bank.
Forward

Reverse

Primer Bank ID

Ccl2

TTAAAAACCTGGATCGGAACCAA

GCATTAGCTTCAGATTTACGGGT

6755430a1

Cd14

CTCTGTCCTTAAAGCGGCTTAC

GTTGCGGAGGTTCAAGATGTT

6753332a1

Hras1

TTTGTGGACGAGTATGATCCCA

TGCTCCCTGTACTGATGGATG

194363765c1

Il10

CTTACTGACTGGCATGAGGATCA

GCAGCTCTAGGAGCATGTGG

291575143c1

Il12a

CAATCACGCTACCTCCTCTTTT

CAGCAGTGCAGGAATAATGTTTC

226874944c1

Irak1

CCACCCTGGGTTATGTGCC

GAGGATGTGAACGAGGTCAGC

21907906a1

Hmgb1

GGCGAGCATCCTGGCTTATC

GGCTGCTTGTCATCTGCTG

6754208a1

Ly86 (Md1)

CTGCCCTCCTTGTGTGGATTC

TGGAACACTGGTCAATGGAAAG

6754588a1

Ly96 (Md2)

CGCTGCTTTCTCCCATATTGA

CCTCAGTCTTATGCAGGGTTCA

8393737a1

Nfkbia (Ikba)

TGAAGGACGAGGAGTACGAGC

TTCGTGGATGATTGCCAAGTG

6754840a1

Pglyrp1

GCCATCCGAGTGCTCTAGC

CTTGTGGTAATGCTGCACATTG

6679293a1

Ptgs2

TTCAACACACTCTATCACTGGC

AGAAGCGTTTGCGGTACTCAT

31127110a1

Rela

AGGCTTCTGGGCCTTATGTG

TGCTTCTCTCGCCAGGAATAC

6677709a1

Ripk2

ATCCCGTACCACAAGCTCG

GGATGTGTAGGTGCTTCACTG

20336736a1

Tlr2

GCAAACGCTGTTCTGCTCAG

AGGCGTCTCCCTCTATTGTATT

31981333a1

Tlr4

ATGGCATGGCTTACACCACC

GAGGCCAATTTTGTCTCCACA

10946594a1

Tlr6

TGAGCCAAGACAGAAAACCCA

GGGACATGAGTAAGGTTCCTGTT

6755815a1

Tnfrsf1a

CCGGGAGAAGAGGGATAGCTT

TCGGACAGTCACTCACCAAGT

31560799a1

Ticam1

AACCTCCACATCCCCTGTTTT

GCCCTGGCATGGATAACCA

23272109a1

Casp8

TGCTTGGACTACATCCCACAC

TGCAGTCTAGGAAGTTGACCA

33859520a1

Chuk

GGTTTCGGGAACGTCAGTCTG

GCACCATCGCTCTCTGTTTTT

242332489c1

Fadd

GCGCCGACACGATCTACTG

TTACCCGCTCACTCAGACTTC

6753812a1

Agfg1

CCCAGACTACAGGTGGAAGTG

CTTTACCCGTGGTCCCAAAAC

26340146a1

Ikbkb

ACAGCCAGGAGATGGTACG

CAGGGTGACTGAGTCGAGAC

33469101a1

Il1r1

GTGCTACTGGGGCTCATTTGT

GGAGTAAGAGGACACTTGCGAAT

6680417a1

Irak2

GGAAGCCGGTTCCTGAGAG

GGCCGGACTTTCTCCTGTTC

26329399a1

Irf3

GAGAGCCGAACGAGGTTCAG

CTTCCAGGTTGACACGTCCG

8393627a1

Map3k7

CGGATGAGCCGTTACAGTATC

ACTCCAAGCGTTTAATAGTGTCG

27881429a1

Nfkb1

ATGGCAGACGATGATCCCTAC

TGTTGACAGTGGTATTTCTGGTG

30047197a1

Nfkb2

TGGCATCCCCGAATATGATGA

TGACAGTAGGATAGGTCTTCCG

293651547c1

Nfkbib

GCGGATGCCGATGAATGGT

TGACGTAGCCAAAGACTAAGGG

24111253a1

Nfkbil1

CCCTGATGCTTACACGGACTT

CAGCCCAGAATCTGCCCAG

6754844a1

Nfrkb

GAAGGGCGTGTTTGACAAGGA

GCATCCCGAACAAGAGACAGAAT

27370138a1

Ppara

AGAGCCCCATCTGTCCTCTC

ACTGGTAGTCTGCAAAACCAAA

31543500a1

Rel

AGAGGGGAATGCGGTTTAGAT

TTCTGGTCCAAATTCTGCTTCAT

6677707a1

Tnfaip3

GAACAGCGATCAGGCCAGG

GGACAGTTGGGTGTCTCACATT

31543880a1

Tradd

GGCAGTGCATACCTGTTTTTG

AACCGCAACTGGACGATGAG

121949761c1

Ube2n

GCTGGCAGAACCAGTTCCT

TCCCTCAAAGGGGGAATCCTG

18017605a1

Ube2v1

GGACCTCCACGAACAATCTATG

GTACTTAGGCCCACACTCTATCT

12848504a1

Clec4d

ACCCGACATCCCCAACTGAT

CTCTCGTCCAGCGTAAAAAGT

6754728a1
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Table 2-1.
Gene

Continued.
Forward

Reverse

Primer Bank ID

Mrc1

CTCTGTTCAGCTATTGGACGC

CGGAATTTCTGGGATTCAGCTTC

6678932a1

Aif1

ATCAACAAGCAATTCCTCGATGA

CAGCATTCGCTTCAAGGACATA

9506379a1

Chrdl1

AACCTCCAAGCCAAAACTTTGA

CCAGTGCTACTTTTCTGGTTGTC

15341247a1

Sparcl1

GGCAATCCCGACAAGTACAAG

TGGTTTTCTATGTCTGCTGTAGC

31982800a1

Aqp4

CTTTCTGGAAGGCAGTCTCAG

CCACACCGAGCAAAACAAAGAT

33563244a1

Cdh5

CACTGCTTTGGGAGCCTTC

GGGGCAGCGATTCATTTTTCT

6753378a1

Nos2

GTTCTCAGCCCAACAATACAAGA

GTGGACGGGTCGATGTCAC

6754872a1

Ccl5

GCTGCTTTGCCTACCTCTCC

TCGAGTGACAAACACGACTGC

7305461a1

Ptgs2

TTCAACACACTCTATCACTGGC

AGAAGCGTTTGCGGTACTCAT

31127110a1

Socs3

ATGGTCACCCACAGCAAGTTT

TCCAGTAGAATCCGCTCTCCT

6671758a1

Pdgfrb

AGGAGTGATACCAGCTTTAGTCC

CCGAGCAGGTCAGAACAAAGG

226342981c1

S100b

TGGTTGCCCTCATTGATGTCT

CCCATCCCCATCTTCGTCC

6677839a1

Csf1r

TGTCATCGAGCCTAGTGGC

CGGGAGATTCAGGGTCCAAG

6681045a1

Siglech

GCTTGTGAACGGGGAACAC

CCCAGGGATATGAGGGCAG

26337567a1

Fos

CGGGTTTCAACGCCGACTA

TTGGCACTAGAGACGGACAGA

6753894a1

Jun

CCTTCTACGACGATGCCCTC

GGTTCAAGGTCATGCTCTGTTT

6754402a1

Hspa1a

TGGTGCAGTCCGACATGAAG

GCTGAGAGTCGTTGAAGTAGGC

387211a1

Cdh5

CACTGCTTTGGGAGCCTTC

GGGGCAGCGATTCATTTTTCT

6753378a1

Ocln

TTGAAAGTCCACCTCCTTACAGA

CCGGATAAAAAGAGTACGCTGG

6679162a1

Slc2a1

CAGTTCGGCTATAACACTGGTG

GCCCCCGACAGAGAAGATG

22094111a1

Cldn5

GCAAGGTGTATGAATCTGTGCT

GTCAAGGTAACAAAGAGTGCCA

31980735a1

Anpep

ACGCTCAGGAGAAGAATAGGAA

CTTAGGCAAGCGATACTGGTTC

225637486c2

Egr1

TCGGCTCCTTTCCTCACTCA

CTCATAGGGTTGTTCGCTCGG

6681285a1

Nr4a1

TTGAGTTCGGCAAGCCTACC

GTGTACCCGTCCATGAAGGTG

6754216a1

Ier3

CAGCCGAAGGGTGCTCTAC

AGCCATCAAAATCTGGCAGAAG

118130957c1

Dusp1

GTTGTTGGATTGTCGCTCCTT

TTGGGCACGATATGCTCCAG

7305423a1

Atf3

GAGGATTTTGCTAACCTGACACC

TTGACGGTAACTGACTCCAGC

31542154a1

Egr3

CCGGTGACCATGAGCAGTTT

TAATGGGCTACCGAGTCGCT

9055212a1

Fosb

TTTTCCCGGAGACTACGACTC

GTGATTGCGGTGACCGTTG

6679827a1

Junb

TCACGACGACTCTTACGCAG

CCTTGAGACCCCGATAGGGA

6680512a1

Ier2

TGACTCTGTCGGTATGGAAGAT

ACCTTGGCTGAGAGGTAGACC

31542990a1

Rplp0

AGATTCGGGATATGCTGTTGGC

TCGGGTCCTAGACCAGTGTTC

6671569a1

Actb

GGCTGTATTCCCCTCCATCG

CCAGTTGGTAACAATGCCATGT

6671509a1

All the above primer sequences were obtained from the primer bank [99-101]
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Table 2-2.
protocols.
Gene

List of RT-qPCR primers from obtained from previously validated

Forward

Reverse

Lcn2

CCAGTTCGCCATGGTATTTT

CACACTCACCACCCATTCAG

Osmr

GTGAAGGACCCAAAGCATGT

GCCTAATACCTGGTGCGTGT

Saa3

GGGTCTAGAGACATGTGGCG

TCTGGCATCGCTGATGACTT

Marco

TTCTGTCGCATGCTCGGTTA

CAGATGTTCCCAGAGCCACC

Msr1

CCAGCAATGACAAAAGAGATGACA

CTGAAGGGAGGGGCCATTTT

Fcrls

GTCGCTGGGGCACTGTATGT

GCACAGGCAGAGCTTCATCAA

Aldh1l1

GCAGGTACTTCTGGGTTGCT

GGAAGGCACCCAAGGTCAAA

Gfap

AGAAAGGTTGAATCGCTGGA

CGGCGATAGTCGTTAGCTTC

Icam1

CACGTGCTGTATGGTCCTCG

TAGGAGATGGGTTCCCCCAG

Tmem119

GTGTCTAACAGGCCCCAGAA

AGCCACGTGGTATCAAGGAG

Tnf

TGTGCTCAGAGCTTTCAACAA

CTTGATGGTGGTGCATGAGA

Il1a

CGCTTGAGTCGGCAAAGAAAT

CTTCCCGTTGCTTGACGTTG

Il1b

TGCCACCTTTTGACAGTGATG

TGATGTGCTGCTGCGAGATT

Il6

TAGTCCTTCCTACCCCAATTTCC

TTGGTCCTTAGCCACTCCTTC

Cxcl10

CCCACGTGTTGAGATCATTG

CACTGGGTAAAGGGGAGTGA

Adora3

TTGCTGGCCATTGCTGTAGA

GAGTGGTAACCGTTCTATATCTGAC

Gapdh

AAGAGGGATGCTGCCCTTAC

TACGGCCAAATCCGTTCACA

All the above primers were obtained from previously published and validated protocols
[102, 103].
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using comparative Ct method [104] and following the minimum information for
publication of quantitative real-time PCR experiments (MIQE) guidelines [105].

RNA Sequencing on Cerebral vessels, Sorted Cerebral Endothelial Cells and
Microglia
Isolated RNA sample quality was determined using High Sensitivity RNA Tapestation
(Agilent Technologies Inc., California, USA) and concentration was measured using the
Qubit 2.0 RNA High Sensitivity assay (ThermoFisher, Massachusetts, USA). Libraries
were then constructed following the manufacturer’s instructions for SMART-Seq® v4
Ultra® Low Input RNA Kit (Takara Bio USA Inc., California, USA) followed by
Nextera® XT DNA Library Prep Kit (Illumina, California, USA). Library concentration
was initially measured using a Qubit 2.0 fluorometer (Life Technologies), and then
diluted to 2 ng/µl before checking insert size on an Agilent 2100 and quantifying to
greater accuracy by KAPA SYBR® FAST quantitative PCR (Roche, Indianapolis, USA)
(library activity >2 nM). Resulting final library size was about 430bp with an insert size
of about 300bp. Illumina® 8-nt dual-indices were used. Equimolar pooling of libraries
was performed based on QC values, and RNA sequencing (RNA-seq) was performed on
an Illumina® NovaSeq 6000 (Illumina, California, USA) for the cerebral vessel samples
or Illumina® HiSeq 4000 (Illumina, California, USA) for sorted CECs and microglia
samples. RNA-seq was performed by Novogene Co. (Sacramento, CA). The read length
configuration was 150 paired end (PE) for 40 million PE reads per sample (20 million in
each direction).

RNA-seq Data Analysis
Transcript abundance from RNA-seq reads was quantified using Salmon [106], and
gene-level counts were obtained using tximport [107], against the C57BL/6J mouse
genome annotation Genome Reference Consortium Mouse Build 38 patch release 6
(GRCm38.p6), obtained from the National Center for Biotechnology Information.
Subsequently, raw counts were processed with DESeq2 [108] to determine differentially
expressed genes. All statistical analyses were conducted using R version 4.0. Multiple
hypothesis correction was done using the Benjamini–Hochberg method, and a P-adjusted
value (p.adj) of 0.05 was considered significant. R package ggplot2 [109] was used for
plotting MA-plots. Heatmaps were generated using R package pheatmap after
normalization of the raw counts using DESeq2, accounting for library size and removing
heteroskedasticity of the counts, and finally the values were Z-scored gene wise. Z-scores
were calculated and obtained on a gene-by-gene basis by subtracting the mean and then
dividing by the standard deviation. In pheatmap, Z-scores are computed after the
hierarchical clustering, so that it only affects the visualization. R package ClusterProfiler
[110] was used to determine gene ontology (GO) categories enriched in the significant
genes from each pairwise comparison. GO terms represented in the dot plots were
selected from the top 10 inflammatory pathways affected in comparison of LPS 4 hours
and PBS in cerebral vessel samples, and these GO terms were used throughout the study
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to monitor the progression in inflammatory gene expression. Fold change values and
statistics for all the comparisons shown in heatmaps are provided in (Appendix-A).

Data Availability
Raw and processed RNA-seq data of the cerebral vessels and the sorted cells are
available at the National Center for Biotechnology Information (NCBI), gene expression
omnibus (GEO) under the accessions GSE155516 and GSE155517.

Code Availability
Code used in the study is available at GitHub and can be accessed from the following
links. The code for cerebral vessel RNA-seq analysis is deposited at
https://github.com/maheshchandrakodali/Cerebral-Vessels-Aug-2020-R-Code
and the code for the microglia and CECs RNA-seq analysis is deposited at
https://github.com/maheshchandrakodali/Sorted-microglia-CECs-Aug-2020-R-Code.
Exosome Isolation, Quantification, Size and Zeta Potential Measurement1
Isolation of exosomes was done using ExoQuick serum exosome precipitation
solution (EXOQ5A-1, Systems Biosciences, San Francisco, CA, USA) according to the
manufacturer’s instructions. Differential ultracentrifugation was done using SW50.2i
rotor on a Beckmann coulter ultracentrifuge, at 20,000 × g at 4°C for 30 minutes to
remove debris and were then centrifuged at 100,000 × g at 4°C for 2 hours. The pellets
which were enriched in exosomes were dissolved in PBS. For quantifying the protein
concentration of exosomes, either intact exosomes were used directly after resuspension
into the PBS or were lysed in 2X radioimmunoprecipitation buffer and sonicated briefly.
The lysates were then centrifuged at 12000 × g at 4°C for 20 minutes. The supernatant
was then quantified by using Pierce BCA protein assay kit (23225, Thermo Fisher
Scientific, Waltham, MA, USA). For measuring the exosome size and zeta potential,
freshly isolated exosome pellets were resuspended in nuclease free water. Size and zeta
potential were measured using Zetasizer Nano-Z (Malvern instruments, Worcestershire,
UK).

Transfusion of Serum Derived Exosomes from Donor to Recipient Mice
Whole blood (700- 800 µl) from mice was collected by cardiac puncture. Blood was
centrifuged at 2,000 × g for 10 min after sitting undisturbed at room temperature for 30
1

This section and the next are modified from final submission with open access permission. Li, J.J., Wang,
B., Kodali, M.C. et al., In vivo evidence for the contribution of peripheral circulating inflammatory
exosomes to neuroinflammation. J Journal of Neuroinflammation, 2018. 15(1): p. 8.
https://doi.org/10.1186/s12974-017-1038-8 [141].
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minutes to separate the serum. Purified exosomes from the sera were then resuspended in
200 μl of sterilized 1X PBS and passed through a 0.22 μm filter before intravenous (IV)
tail vein injection to the recipient mice.
In our pilot study, we transfused 3 different doses (500 μg, 1 mg, and 1.5 mg) of total
exosomes (as measured by total protein concentration), derived from the mice treated
with LPS (5mg/kg, 24 hours), and found that both 1 mg and 1.5 mg of exosomes induced
significant increase of microglial activation in the recipient mice while 500 μg failed to
achieve such effect. We therefore used a 1 mg exosome dose throughout the remainder of
the study. Equal numbers of male and female mice were included.
For the follow-up experiments of injecting LPS-exosomes to recipient mice
intravenously via tail vein and intracerebroventricularly (ICV), a total of 12 mice (12
donor and 12 recipient mice of wild type young adult B6) were used. Donor mice
received either PBS (n=6) or LPS (n=6; 5mg/kg) for 24 hours. Whole blood was
collected, and exosomes were isolated from sera using ExoQuick kit and resuspended in
sterile PBS (1 mg in 20 ul of saline for intracerebroventricular injection or infusion and in
200 ul for tail vein injection into each mouse). Intracerebroventricular infusion of 1 mg of
exosomes (as measured by total protein concentration) in 20 ul was performed via
implanted cannulas, as described in our previous work [111], over a course of 1 hour at a
speed of 0.16 ul/min. A total of 6 recipient mice received exosomes via ICV infusion and
another 6 mice received tail vein injection of the resuspended exosomes (PBS or LPS;
n=3/group). Mice were all sacrificed 24 hours after receiving exosomes followed up by
immunohistochemical examination of histological markers.

Brain Section Immunohistochemistry
Mice were perfused with 4% paraformaldehyde (PFA), and isolated brains were fixed
in 4% PFA overnight at 4°C followed by cryoprotection in 20% sucrose and finally in
30% sucrose. Sixteen micrometer coronal sections were cut with a microtome and
attached onto superfrost slides (#12-550-15, Fisher Scientific, Hampton, NH, USA).
Sections were then washed in PBS, non-specific binding was then blocked with PBS
containing 0.5% Triton X-100, and 5% donkey serum for 30 minutes, and then incubated
in primary antibody diluted in blocking solution overnight at 4°C (mouse anti-GFAP
(Millipore, MAB3402); rabbit anti-IBA1 (Wako, 019-19741); and anti-F4/80 (rat
polyclonal, Abcam Ab6640; 1:100). The sections were then washed two times and
incubated in appropriate secondary antibodies for 1 hour at room temperature and
mounted in DAPI solution after final washing.
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Digital Image Quantification2
Images with a resolution of 4080 × 3072 pixels were captured with an Olympus IX50
microscope (Olympus Corporation, Shinjuku, Tokyo, Japan). Images of hippocampus
and neocortex regions were taken. A total of about 65 coronal sections (16 μm per
section) through the hippocampal region of each animal mouse were sliced, and one
section out of every ten sections were collected to constitute a six-section serial set,
which were stained and then the staining intensity was quantified. Before the acquisition
of each image, the sections were examined carefully to know if the hippocampal and
neocortical structures were intact and if the sections were flattened and not folded. Six to
eight images per structure per animal were captured, covering as many sections as
possible from the six-section serial set. Exposure time was manually adjusted to
minimize saturation while maintaining adequate signal-to-background contrast. Images
from the same antibodies were acquired using the same exposure time. The images were
converted to 680 × 512 pixels and analyzed using ImageJ software (National Institutes of
Health, Bethesda, MD; http://imagej.nih.gov/ij/). Image files were converted to RGB
stacks and color-inverted, converting the color images to grayscale mode. Then, the
threshold of the images was adjusted to define the positive signals from the surrounding
background. The total staining intensities were expressed by integrated intensity (i.e.
mean gray value × area) using the ROI manager function of ImageJ. Areas of positive
aggregates were identified between 3 to 500 pixels^2 with circularity of 0 to 1. Areas of
false-positive aggregates with no cell morphology were manually excluded. The average
value from the 6-8 images was used to represent the value from one mouse brain.

Western Blot Analysis
Western blotting analyses were performed by using 20 μg of total protein per sample
as described previously [112]. Antibodies used were anti-TSG101 antibody (SC-7964,
Santa Cruz Biotechnology, Dallas, TX, USA), ALIX (12422-1-AP, Proteintech, IL,
USA) and anti-β-Actin antibody (#A2228, Sigma-Aldrich, St Louis, MO, USA).

Statistics
All statistical analyses (excluding RNA-seq data) were conducted using GraphPad
Prism v. 8 (GraphPad Software, San Diego, CA). Data are presented as mean ± standard
error of the mean (SEM). The sample size for each experiment, and the statistical testing
methods are reported in the figure legends.

2

This section and the next are modified from final submission with open access permission. Li, J.J., Wang,
B., Kodali, M.C. et al., In vivo evidence for the contribution of peripheral circulating inflammatory
exosomes to neuroinflammation. J Journal of Neuroinflammation, 2018. 15(1): p. 8.
https://doi.org/10.1186/s12974-017-1038-8 [141].
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CHAPTER 3. PROGRESSION OF MOLECULAR SEQUALAE IN THE BRAIN
DURING THE INITIATION OF SEPSIS-ASSOCIATED ENCEPHALOPATHY
FOLLOWING SYSTEMIC INFLAMMATION

Introduction
Sepsis-associated encephalopathy (SAE) is an acutely progressing brain dysfunction
that accompanies systemic inflammatory response syndrome or sepsis induced systemic
inflammation and is characterized by the absence of direct CNS infection [18]. It is the
most common type of encephalopathy encountered by patients in the intensive care unit
[19] and about 750,000 cases are reported annually in the United States alone, of which
about 62% require rehospitalization [20]. It is very often associated with increased
mortality, and the recovered patients often display chronic neurological dysfunction with
cognitive deficits [18, 19].
Neuroinflammation, vascular dysfunction and BBB disruption are all proposed to play
important roles in the progression of SAE [24]. A widely accepted mechanism proposes
that altered brain perfusion and cerebral endothelial cell activation results in impaired
BBB and the subsequent cerebral dysfunction [20, 25, 26]. Microglial and astrocytic
activation also occur, resulting in neuroinflammation and increase in the CNS cytokine
levels and thus causing delirium and sickness behavior [16, 113]. Vascular dysfunction
and glial cell activation are the two major components of this mechanism. Previous
studies suggest that the cerebral blood vessels are initially affected in the CNS during
acute systemic inflammatory conditions [114] and that they mediate further cytokine
dependent signaling [115]. The gene Nfkbia, which reflects the activity of transcription
factor NF-κB was found alongside the vasculature at 30-60 minutes after the induction of
systemic inflammation [114, 116]. However, the global transcriptional profiles of
inflammatory signaling during such and the underlying pathophysiology are not
completely characterized. In particular, the immediate effects of systemic inflammation
on the cerebral vasculature before advancing to vascular dysfunction are not fully
understood yet.
The cells of cerebral vasculature include the vascular endothelial cells and pericytes
surrounded by the astrocyte end feet which together form the BBB [30]. BBB is an
anatomical gateway of cerebrovascular system responsible for the immune privilege of
the CNS, which isolates the CNS from the peripheral immune system and regulates
physiological communication between them [117]. Initial effects of systemic
inflammation on the cerebral vasculature include molecular changes which are
anatomically non-disruptive in nature and are believed to occur earlier during the
initiating phase of SAE [71]. There is little knowledge about the cell types in which such
initial molecular events occur. The chronology of such molecular sequelae leading to
SAE remain elusive. Furthermore, the cellular pathophysiology of the onset of SAE
remains poorly understood. It is unclear whether vascular activation or microglial
activation occurs initially which plays a determining role in the SAE progression. To
prevent sepsis-associated BBB dysfunction and neuro-cognitive damages, it is imperative
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to know the immediate events and the precise order in which they occur in the CNS
during the initiation of SAE, as well as the contribution and interplay of the involved cell
types.

Results

Cerebral vessels elicit proinflammatory responses during SAE
To examine the effects of systemic inflammation on the CNS, we initially looked at
the gene expression in the whole forebrains isolated from the mice injected
intraperitoneally with LPS. We detected significant changes in the widely reported
inflammatory cytokine and chemokine gene expression (Figure 3-1A through H). We
also detected changes in pan reactive genes Lcn2, Osmr, Saa3 (Figure 3-2A through C)
as well as microglia related Marco, Msr1, Clec4d, Mrc1, Fcrls (Figure 3-2D through H),
astrocyte related Chrdl1, Gfap, Sparcl1, Aqp4 (Figure 3-2I through K) and cerebral
endothelial cell related Icam1, Cdh5 (Figure 3-2M, N). In order to study the effects on
the cerebral vasculature, we isolated the cerebral vessels from the brains of the mice. To
confirm the identity of these isolated vessels we stained them for vascular cell markers
GLUT1, COL-IV, CD13 and CD31 (Figure 3-3A through C). Canonical cerebral
endothelial cell (CEC) marker genes were found to be selectively enriched in the isolated
vessels compared to the vessel depleted brain fractions (Figure 3-4A through I). To
examine if the inflammatory changes could be detected in the cerebral vasculature, we
performed RT-qPCR analysis of the RNA from the cerebral vessels isolated from the
mice after LPS challenge for 4 hours and 24 hours. Significant alteration of
proinflammatory cytokine genes Tnf, Il1a, Il1b and Il6 (Figure 3-5A through D) and
chemokine genes Ccl2 and Ccl5 (Figure 3-5E, F) as well as proinflammatory genes
Nos2, Ptgs2, Socs3 and Saa3 (Figure 3-5G through J) demonstrated the effect of
systemic inflammation on the cerebral vessels in the CNS.

Acute systemic inflammation rapidly affects the cerebral vessels during the
initiation of SAE
After detecting the transcriptional changes in the isolated cerebral blood vessels
during systemic inflammation, we next wanted to know how soon the changes occur in
the cerebral vasculature in response to systemic inflammation. To capture the global gene
expression patterns in the cerebral vasculature following acute systemic inflammation,
RNA-seq was performed on the isolated cerebral vessels from the mice at 15 minutes, 30
minutes, and 4 hours after receiving LPS. Analysis of the RNA-seq data followed by the
principal component analysis (PCA) showed a clear separation among these treatment
timepoints (Figure 3-6). The scatterplot matrix shows the expression levels of all the
pairwise comparisons of the LPS treatments to PBS control (Figure 3-7A). Moreover,
unsupervised hierarchical clustering of samples also displayed distinct grouping
according to the treatment groups (Figure 3-7B).
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Figure 3-1. Expression of proinflammatory genes in the forebrain during systemic
inflammation.
A through H. mRNA fold change levels in whole forebrain lysates from the mice injected
with 10mg/kg LPS for 24 hours, Tnf, Il1a, Il1b, Il6, Nos2, Socs3, Ccl2 and Ccl5 (n = 6-8
(male and female) mice in each group, Mann-Whitney test, *p<0.05, **p<0.01,
***p<0.001).
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Figure 3-2. Expression changes of cell-type specific genes detected in the brain
following systemic inflammation.
A through N. mRNA fold change levels in whole forebrain lysates from the mice injected
with 10mg/kg LPS for 24 hours, (A through C) pan reactive genes Lcn2, Osmr, Saa3, (D
through H) microglia related genes Marco, Msr1, Clec4d, Mrc, Fcrls, (I through L)
Astrocyte related genes Chrldl1, Gfap, Sparcl1, Aqp4, (M, N). CEC related genes Icam1
and Cdh5. (n = 6-8 (male and female) mice in each group, Mann-Whitney test, *p<0.05,
**p<0.01, ***p<0.001).
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Figure 3-3.

Characterization of isolated cerebral vessels.

A through K. Confocal images of immuno-stained isolated cerebral vessels for
endothelial cell markers COL-IV, GLUT1, CD13 and CD31, (A) red channel is GLUT1,
green channel is COL-IV, (B) red channel is GlUT1, green channel is CD13 and blue
channel is DAPI, (C) green channel is CD31, blue channel is DAPI . (n=3 male mice).
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Figure 3-4.

Expression of vascular cell markers in the isolated cerebral vessels.

A through I. RT-qPCR analysis confirmed that the isolated cerebral vessels are enriched
for expressing vasculature specific markers compared to the cerebral vessel depleted
fractions, (A) Cdh1, (B) Pdgfrb, (C through E) Gfap, S100b and Aldh1l1, (F through H)
Aif1, Csf1r, Tmem119 and Siglech, (n= 6-7 males in each group), Bars represent mean ±
SEM.

26

Figure 3-5. Expression of proinflammatory genes in the isolated cerebral vessels
during sepsis-associated encephalopathy.
A through J. mRNA fold change levels of various proinflammatory genes in cerebral
vessels isolated from the brains of the mice injected with 10mg/kg LPS for 4 hours and
24 hours, (A through D) proinflammatory cytokines Tnf, Il1a, Il1b, Il6, (E, F)
chemokines Ccl2, Ccl5, (G through J) inflammation induced genes Nos2, Ptgs2, Socs3
and Saa3, (n= 3-4 male mice in each group, One-way ANOVA followed by Tukey’s
post-hoc test, *p<0.05, **p<0.01, ***p<0.001).
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Figure 3-6.

PCA plot of RNA-seq data from cerebral vessels.

PCA plot of the RNA-seq data from cerebral vessels isolated from the brains of mice
injected with 10mg/kg LPS for 15 minutes, 30 minutes and 4 hours or PBS. (n=3 in each
group, every sample in each group includes the cerebral vessels from one male and one
female mice pooled together).
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Figure 3-7.
vessels.

Scatter plot and correlation plot of RNA-seq data from cerebral

A. Scatter plot matrices showing the FPKM distributions (histograms) and correlation
(Corr) values, B. Unsupervised hierarchical clustering showing the sample to sample
distances of the RNA-seq data from the cerebral vessels isolated from the brains of mice
treated with 10mg/kg LPS for 15 minutes, 30 minutes, 4 hours and PBS. (n=3 in each
group, every sample in each group includes the cerebral vessels from one male and one
female mice pooled together).
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Further analysis revealed the differential expression of 457, 558, and 4543 genes
significantly (p.adj < 0.05 and log fold change (LFC) > 1.5) during the treatment
timepoints 15 minutes, 30 minutes and 4 hours respectively compared to the baseline
PBS control (Figure 3-8A through C).
We then looked at the progression of immediate early genes (IEGs) [118], which
indicate the earliest inflammatory responses. There was a rapid induction of IEGs in the
blood vessels as early as 15 minutes and peaking at 30 minutes post LPS (Figure 3-9,
Tables A-1 through A-3). We also observed the changes in the genes belonging to the
GO term response to lipopolysaccharide (GO:0032496) at 15 minutes, suggesting the
immediate effect of peripheral inflammation on the cerebral blood vessels (16 genes,
Figure 3-10, Table A-4). Next, we observed distinct changes at 30 minutes in the genes
belonging to positive regulation of NF-κB transcription factor activity (GO:0051092),
response to lipopolysaccharide (GO:0032496), positive regulation of cytokine production
(GO:0001819) and tumor necrosis factor production (GO:0032640) (67 genes, Figure
3-11, Table A-5), suggesting the rapid activation of proinflammatory signaling. Gene
ontology enrichment was done on the differentially expressed significant genes, and the
dot plots show the progression of selected GO terms related to inflammatory signaling at
each time point, further indicating the immediate induction of proinflammatory signaling
in the vasculature in samples as early as 15 minutes after peripheral LPS injection
(Figure 3-12A through C). Consistent with the previous reports [114], our results
indicated that Nfkbia begins to increase as early as 15 minutes following the peripheral
inflammatory insult. Furthermore, we also observed that the genes regulating the blood
vessel morphology were vastly affected at 15 minutes (Figure 3-13A, Table A-6), and
the genes regulating the blood vessel size and diameter at 30 minutes (Figure 3-13B,
Table A-7). At 4 hours, the genes regulating the establishment of endothelial barrier were
affected which suggest the functional effects of proinflammatory signaling on the
vasculature i.e. rapid progression towards blood brain barrier disruption (Figure 3-14A,
Table A-8). The dot plot shows the changes in GO terms related to the blood brain
barrier integrity, and the number of associated genes which were significantly affected at
4 hours post LPS injection (Figure 3-14B). Together, these results suggest the
progression of inflammatory response into the CNS by beginning with the activation of
inflammatory signaling in the vasculature, and simultaneously affecting the blood vessel
size and diameter, continued by rapid inflammatory signaling, and finally the induction of
endothelial apoptotic signaling and dysregulation of endothelial barrier.
To further confirm the RNA-seq results and to know how earliest the peripheral
inflammation induces the changes in the cerebral vasculature, we performed a similar
time course study to look at the pattern of the changes in the gene expression of the blood
vessels. We thus isolated the cerebral vessels from the brains of the mice which were
injected with LPS and sacrificed after 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours,
and 4 hours. RT-qPCR results confirmed the rapid induction of immediate early response
genes Fos, Jun and Hspa1a1 in the blood vessels (Figure 3-15A through C). Of note, this
early response was found to be significantly enriched in the vessels compared to the
remaining brain fractions after vessel depletion (as indicated by the asterisks), suggesting
the important role of vasculature-mediated inflammatory wave propagation into the CNS.
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Figure 3-8. MA plots showing the pairwise comparisons of RNA-seq data from
cerebral vessels.
A through C. MA plots of the pairwise comparisons of cerebral vessels for the LPS
treatment timepoints (A) 15 minutes, (B) 30 minutes and (C) 4 hours compared to PBS;
log fold changes (LFCs) are plotted against the mean of normalized counts to determine
the variance between two treatments in terms of gene expression. Red nodes on the graph
represent statistically significant data points i.e. p.adj < 0.05 and LFC > 1.5. Gray nodes
are data points that are not statistically significant. Numerical values in parentheses for
the significant legend indicate the number of genes that meet the prior condition. Dashed
lines indicate the cutoff LFC values. (n=3 in each group, every sample in each group
includes the cerebral vessels from one male and one female mice pooled together).
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Figure 3-9.

Heatmap of immediate early genes expression in cerebral vessels.

Heatmap showing the progression of immediate early genes activation in the cerebral
vessels, (significant genes (p.adj < 0.05 and LFC > 1.5) in LPS 15 minutes, 30 minutes
and 4 hours compared to PBS); (n=3 in each group, every sample in each group includes
the cerebral vessels from one male and one female mice pooled together).

34

Figure 3-10. Heatmap of the genes showing inflammatory response in cerebral
vessels at 15 minutes post LPS treatment.
Heatmap showing the significant (p.adj < 0.05 and LFC > 1.5) genes belonging to gene
ontology term response to lipopolysaccharide (GO:0032496), in the cerebral vessels from
the LPS treatment time points 15 minutes. (n=3 in each group, every sample in each
group includes the cerebral vessels from one male and one female mice pooled together).
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Figure 3-11. Heatmap of the genes showing inflammatory response in cerebral
vessels at 30 minutes post LPS treatment.
Heatmap showing the progression of significant genes belonging to gene ontology (GO)
terms positive regulation of NF-κB activity (GO:0051092), response to
lipopolysaccharide (GO:0032496), positive regulation of cytokine production
(GO:0001819) and tumor necrosis factor production (GO:0032640), in the cerebral
vessels from the LPS treatment time points 15 minutes and 30 minutes (significant genes
(p.adj < 0.05 and LFC > 1.5) in LPS 30 minutes compared to PBS); (n=3 in each group,
every sample in each group includes the cerebral vessels from one male and one female
mice pooled together).
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Figure 3-12. Gene ontology enrichment plots showing the pairwise comparisons of
RNA-seq data from cerebral vessels.
A through C. Gene ontology (GO) enrichment dot plots showing the number of genes
affected and the top 10 enriched inflammation related GO terms in the cerebral vessels
from (A) 15 minutes, (B) 30 minutes and (C) 4 hours LPS treatment compared to PBS;
(n=3 in each group, every sample in each group includes the cerebral vessels from one
male and one female mice pooled together).
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Figure 3-13. Heatmaps of the genes related to regulation of vascular tone in
cerebral vessels at 15 minutes and 30 minutes post LPS treatment.
A. Heatmap showing the significant (p.adj < 0.05 and LFC > 1.5) genes belonging to
gene ontology term negative regulation of blood vessel morphogenesis (GO:200018), in
the cerebral vessels from the LPS treatment time point 15 minutes. B. Heatmap showing
the progression of significant genes belonging to gene ontology term regulation of blood
vessel diameter (GO:0097746), in the cerebral vessels from the LPS treatment time point
15 minutes and 30 minutes (significant genes (p.adj < 0.05 and LFC > 1.5) in LPS 30
minutes compared to PBS); (n=3 in each group, every sample in each group includes the
cerebral vessels from one male and one female mice pooled together).
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Figure 3-14. Effects of systemic inflammation on endothelial barrier integrity in
cerebral vessels.
A. Heatmap showing the progression in significant genes belonging to gene ontology
term establishment of endothelial barrier (GO:0061028), in the cerebral vessels from the
LPS treatment time points 15 minutes, 30 minutes and 4 hours (significant genes (p.adj <
0.05 and LFC > 1.5) in LPS 4 hours compared to PBS, B. Gene ontology (GO)
enrichment dot plots showing the number of genes affected and the top 10 enriched
barrier related GO terms in the cerebral vessels at 4 hours LPS treatment compared to
PBS.
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Figure 3-15. RT-qPCR confirmation of immediate early gene expression in
cerebral vessels.
A through C. Time course of (A) Fos, (B) Jun and (C) Hspa1a mRNA fold changes in
cerebral vessels and cerebral vessels depleted fractions, isolated from the brains of mice
treated with 10mg/kg LPS for 5 minutes, 15 minutes, 30 minutes, 1 hour, 4 hours, 24
hours and PBS, graphs depict mean ± SEM, n= 8 (4 males and 4 females in each group),
Two-way ANOVA with Dunnett post-hoc test, *p<0.05, **p<0.01, ***p<0.001.
Asterisks indicate significance at that particular treatment time point between the groups
cerebral vessels and cerebral vessel depleted brain fractions. The comparison of cerebral
vessels with the respective PBS control also yielded significant results, but were not
depicted.

40

41

We also found that the genes related to the GO terms response to lipopolysaccharide and
positive regulation of NF-κB signaling were significantly altered during the initiation of
acute neuroinflammation, which confirmed the results obtained from the RNA-seq
analysis on the cerebral vessels (Figure 3-16A, B).

Cerebrovascular cells are affected during SAE
To identify which specific cell type(s) were responsible for the transcriptional changes
detected in the cerebral vessels as well as to pinpoint the individual contribution of each
of the predominant cell types in the CNS, we designed a flow cytometry surface staining
panel and validated a gating scheme to simultaneously label and sort all the major nonneuronal gliovascular cells (CECs, microglia, astrocytes and pericytes) from an adult
mouse brain. We then injected the mice with LPS and sacrificed them after 4 hours and
24 hours, immediately followed by the isolation of the brains and dissociation to yield
single cell suspension, immunolabelling and finally sorting them using fluorescenceactivated cell sorting (FACS). Microglia, CECs, pericytes, astrocytes were defined and
gated as CD45 low-mid CD11b+ [119], CD45- CD13- CD31+ [120, 121], CD45- CD31CD13+ [121], and CD45- CD31- CD13- O4- ACSA2+ [122, 123] respectively, as shown
in the representative gating scheme (Figure 3-17A, B). Only surface markers were used
to avoid cell permeabilization, and dead cells were excluded to ensure respective cell type
identity and sorted cell quality during the sorting. We then performed RT-qPCR on the
RNA isolated from the sorted individual cell lysates. Our results revealed that not only
the microglia and astrocytes responded to acute systemic inflammation, but also the
cerebrovascular endothelial cells as well as pericytes displayed proinflammatory
transcriptional changes at 4 hours and 24 hours post peripheral inflammatory insult
(Figure 3-18A through H) suggesting that the results we obtained earlier on the isolated
cerebral vessels might be due to the responses in these vascular cells. In order to further
confirm the identity of the sorted cells, we analyzed the lysates for the cell type specific
marker genes using RT-qPCR i.e. Aif1/Iba1, Siglech, Tmem119 and Csf1r for microglia,
Aldh1l1, Gfap, S100b and Aqp4 for astrocytes, Cdh5, Ocln, Glut1, and Cldn5 for CECs,
Pdgfrb and Anpep for pericytes. We then found the appropriate enrichment or depletion
of each cell type specific marker transcripts in the respective sorted immunolabelled
target populations, further confirming the purity of the isolated cell populations (Figure
3-19A through O).

Temporal transcriptional profiling of CECs and microglia reveal individual cell
type specific gene expression kinetics during the initiation of SAE
Though we were able to identify that the vascular cells are affected during systemic
inflammation, it is still unclear about which cell type in the vasculature initially senses or
responds to acute systemic inflammation and additionally, if this response is a result of
peripheral inflammation or a result of glial cell responses in the CNS. After the initial
validation of our method to sort the various cells in the CNS, we next wanted to find out
which vascular cell type mediates the acute inflammatory responses detected in the
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Figure 3-16. Heatmaps from the RT-qPCR data on the cerebral vessels for genes
belonging to LPS response and NF-κB signaling.
A, B. Heatmaps of the Z-scores from the RT-qPCR on the cerebral vessels for the genes
related to GO terms (A) response to lipopolysaccharide and (B) positive regulation of
NF-κB signaling. graphs depict mean ± SEM, n= 8 (4 males and 4 females in each
group).
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Figure 3-17. FACS strategy for the simultaneous sorting of gliovascular cells from
an adult mouse brain.
A. Schematic illustration showing the experimental design B. FACS strategy for the
simultaneous sorting of gliovascular cells from an adult mouse brain, microglia, CECs,
pericytes, astrocytes were defined and gated as CD45 low-mid CD11b+, CD45- CD13CD31+, CD45- CD31- CD13+, and CD45- CD31- CD13- O4- ACSA2+ respectively.
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Figure 3-18. Expression of proinflammatory genes in the sorted gliovascular cell
populations from mouse brain.
A through H. Time course of mRNA fold change in microglia, astrocytes, CECs and
pericytes isolated from the brains of mice injected with 10mg/kg LPS for 4 hours and 24
hours, (A) Tnf, (B) Il1a, (C) Il6, (D) Lcn2, (E) Ccl2 , (F) Cxcl10, (G) Ptgs2 and (H)
Socs3. Graphs depict mean ± SEM, n= 4 (females) each group, Two-way ANOVA with
Dunnett post-hoc test, *p<0.05, **p<0.01, ***p<0.001. Asterisks indicate significance at
that particular treatment time point as compared to the respective PBS group in each of
the cell types. The comparison between the cell types at each of the time points also
yielded few significant results, but were not depicted.
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Figure 3-19. Expression of cell-type specific markers in sorted gliovascular cell
populations from mouse brain.
A through O. RT-qPCR analysis confirmed that the FACS sorting enriched for cells
expressing cell type specific markers, (A through E) CD45 low-mid CD11b+ sorting
enriched for cells expressing microglial markers, (F through I) CD45- CD13- CD31+
sorting enriched for cells expressing cerebral endothelial cell markers, (J and K) CD45CD31- CD13+ sorting enriched for cells expressing pericyte markers, and (L through O)
CD45- CD31- CD13- O4- ACSA2+ sorting enriched for cells expressing astrocytic
markers, n=4 (males) Bars represent mean ± SEM.
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cerebral blood vessels and to determine how these responses compare to the responses in
resident myeloid cells i.e. microglia. Such a comparative study would allow us to
sequentially visualize and contrast the cell type specific progression of inflammatory
events as a function of time. Given that endothelial cells being the principal vascular cell
type lining the blood vessels, we hypothesized that CECs could be the key players in
mediating the acute inflammatory responses seen in the cerebral vasculature. We thus
treated the mice with LPS for 15 minutes, 30 minutes, 1 hour, 2 hours and 4 hours,
followed by FACS to collect the gliovascular cells. RNA-seq was then performed on the
RNA from CECs and microglia at the timepoints 30 minutes, 1 hour, 2 hours and PBS.
We chose 30 minutes as this was the time point when we saw a maximal initial response
in the isolated cerebral vessels. RNA-seq data analysis followed by the PCA analysis
showed a clear separation among the cell type (PC1 – 94% variance) as well as the
treatment (PC2 – 4% variance) (Figure 3-20A). The scatterplot matrices show the
expression levels of all the pairwise comparisons of the LPS treatments to PBS control in
CECs (Figure 3-20B) and in microglia (Figure 3-20C). We further confirmed the cell
type identities by comparing microglia and CECs; and found the exclusive enrichment of
several cell type specific markers in each of the respective cell types (Figure 3-21).
Further analysis to determine the effect of LPS treatment within each cell type revealed
the differential expression of 17, 58, and 601 genes in microglia (Figure 3-22A through
C); whereas 318, 663, and 4244 genes in CECs (Figure 3-22D through F) significantly
(p.adj < 0.05 and LFC > 1.5) during the treatment timepoints 30 minutes, 1 hour and 2
hours in each respectively. These differentially expressed significant genes were obtained
by using the Wald test in DESeq2 analysis, by computing the individual pairwise
comparison to the respective cell type PBS control, at each of the time points. We next
observed the rapid induction of immediate early response genes exclusively in CECs but
not in microglia as early as 30 minutes and peaking at 1 hour post LPS (Figure 3-23,
Table A-9 through A-13) suggesting the immediate activation of CECs during systemic
inflammatory conditions. From each set of the significant genes from the pairwise
comparisons at each time points in microglia and CECs, we closely looked at the genes
related to the gene ontology (GO) biological process terms positive regulation of NF-κB
transcription factor activity (GO:0051092), response to lipopolysaccharide
(GO:0032496), positive regulation of cytokine production (GO:0001819) and tumor
necrosis factor production (GO:0032640) to monitor the progression of peripheral
inflammation into the CNS. We found clear changes in expression of 19 genes belonging
to the above GO terms in CECs at 30 minutes (Figure 3-24, Table A-14). Strikingly,
there were no genes found to be altered in microglia at 30 minutes, indicating that there is
not yet an induction of inflammatory responses in microglia at 30 minutes. At 1 hour
timepoint, we found the changes in 48 genes in CECs (Figure 3-25A, Table A-15), while
7 genes in microglia appear to change (Figure 3-25B, Table A-16), together suggesting
that the inflammatory response occurs earlier in the CECs at 30 minutes followed later in
microglia at 1 hour in the CNS. At 2 hours, we found 161 genes in CECs and 71 genes in
microglia, suggesting the induction of inflammatory responses in microglia too alongside
CECs. Gene ontology enrichment was done on the significant genes, and the dot plots
show the progression of selected GO terms related to inflammatory response at 30
minutes in CECs (Figure 3-26A), while no enrichment was found in microglia plausibly
because of very few significantly changed genes. However, at 1 hour, while CECs have
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Figure 3-20. PCA plot and Scatter plots of the RNA-seq data from sorted microglia
and cerebral endothelial cells.
A. PCA plot of the RNA-seq data from microglia and CECs isolated from the brains of
mice injected with 10mg/kg LPS for 30 minutes, 1 hour and 2 hours or PBS n= 3 (males)
each group. (B, C). Scatterplot matrices showing the FPKM distributions (histograms)
and correlation (Corr) values of the RNA-seq data from (B) CECs and (C) microglia
isolated from the brains of mice injected with 10mg/kg LPS for 30 minutes, 1 hour and 2
hours or PBS n= 3 (males) each group.
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Figure 3-21. Heatmap of cell-type specific marker genes in microglia and cerebral
endothelial cells.
Heatmap showing the enrichment of cell type specific marker genes in microglia and
CECs, n= 3 (males) each group.
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Figure 3-22. MA plots showing the pairwise comparisons between each timepoint
post LPS treatment in sorted microglia and cerebral endothelial cells.
A through F. MA plots of the pairwise comparisons in microglia between the timepoints
(A) 30 minutes, (B) 1 hour and (C) 2 hours compared to PBS (microglia); and in CECs
for the LPS treatment timepoints (D) 30 minutes, (E) 1 hour and (F) 2 hours compared to
PBS (CECs). log fold changes (LFCs) are plotted against the mean of normalized counts
to determine the variance between two treatments in terms of gene expression. Red nodes
on the graph represent statistically significant data points i.e. p.adj < 0.05 and LFC > 1.5.
Gray nodes are data points that are not statistically significant. Numerical values in
parentheses for the significant legend indicate the number of genes that meet the prior
condition. Dashed lines indicate the cutoff LFC values. n= 3 (males) each group.
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Figure 3-23. Heatmap of immediate early genes expression in microglia and
cerebral endothelial cells.
Heatmap showing the progression of immediate early genes in the microglia and CECs,
(significant genes (p.adj < 0.05 and LFC > 1.5) in CECs, at LPS 30 minutes, 1 hour and 2
hours compared to PBS); n= 3 (males) each group.
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Figure 3-24. Heatmap of the genes showing inflammatory response in microglia
and cerebral endothelial cells at 30 minutes post LPS treatment.
Heatmap showing the progression of significant genes belonging to gene ontology terms
positive regulation of NF-κB activity (GO:0051092), response to lipopolysaccharide
(GO:0032496), positive regulation of cytokine production (GO:0001819) and tumor
necrosis factor production (GO:0032640), in microglia and CECs from the LPS treatment
time point 30 minutes (significant genes (p.adj < 0.05 and LFC > 1.5) in CECs LPS 30
minutes compared to CECs PBS); n= 3 (males) each group.
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Figure 3-25. Heatmap of the genes showing inflammatory response in microglia
and cerebral endothelial cells at 1-hour post LPS treatment.
A. Heatmap showing the progression of significant genes belonging to gene ontology
terms positive regulation of NF-κB activity (GO:0051092), response to
lipopolysaccharide (GO:0032496), positive regulation of cytokine production
(GO:0001819) and tumor necrosis factor production (GO:0032640), in microglia and
CECs from the LPS treatment time points 30 minutes and 1 hour (significant genes (p.adj
< 0.05 and LFC > 1.5) in CECs LPS 1 hour compared to CECs PBS), B. Heatmap
showing the significant (p.adj < 0.05 and LFC > 1.5) genes belonging to gene ontology
term response to lipopolysaccharide (GO:0032496) in microglia from the LPS treatment
time point 1 hour, n= 3 (males) each group.
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Figure 3-26. Gene ontology enrichment plots showing the pairwise comparisons
between each timepoint post LPS treatment in sorted microglia and cerebral
endothelial cells.
A through E. GO enrichment dot plots showing the number of genes affected in top 10
enriched inflammation related GO terms (A) in CECs from 30 minutes LPS treatment
compared to PBS, (B) in CECs from 1 hour LPS treatment compared to PBS (C) in
microglia from 1 hour LPS treatment compared to PBS (D) in CECs from 2 hours LPS
treatment compared to PBS, (E) in microglia from 2 hours LPS treatment compared to
PBS, n= 3 (males) each group.

59

60

substantially increased differentially expressed genes in each GO term compared to
earlier 30 minutes indicating the progression of inflammation (Figure 3-26B), few GO
terms begin to be enriched in microglia at 1 hour (Figure 3-26C). Finally, at 2 hours, all
the terms appear from CECs as well as from microglia, suggesting the induction of
inflammatory responses in both cell types by this time point. However, there were still
much larger number of genes which were significantly affected in CECs compared to that
in microglia at 2 hours (Figure 3-26D, E).
Additionally, likelihood ratio test (LRT) [108] was done by using a reduced model as
the design formula in DESeq2, which identified the differentially expressed genes
between the cell types at each time point by taking the baseline expression of the
respective cell type PBS controls into consideration to determine the changes in gene
expression patterns, and the significant genes were returned whose pattern of expression
is different from that of the reference cell type. This further revealed that 90, 202, and
2078 genes were differentially expressed in CECs compared to microglia at each of the
time points 30 minutes, 1 hour and 2 hours post LPS injection respectively (Figure
3-27A through C). Gene ontology enrichment was done on these significant genes, and
the dot plots show the initiation of all selected GO terms related to inflammatory
response at 30 minutes (Figure 3-28A), further progressing at 1 hour and 2 hours in
CECs compared to microglia (Figure 3-28B, C).
In addition, the genes regulating the blood vessel size and diameter, cell-cell adhesion
were also affected in CECs at 30 minutes (Figure 3-29, Table A-17). At 2 hours, the
genes regulating the establishment of endothelial barrier and endothelial apoptotic
signaling were affected (Figure 3-30A, Table A-18) further confirming our data on the
cerebral vessels. This suggests that the functional effects on the cerebral vasculature are
mediated through major transcriptional changes in the CECs which continue to progress
after the initial proinflammatory signaling, leading towards blood brain barrier disruption.
The dot plot shows the changes in GO terms related to the BBB integrity, and the number
of associated genes which were significantly affected in CECs at 2 hours post LPS
injection (Figure 3-30B). Together, these results suggest the progression of inflammatory
response into the CNS by beginning with the activation of inflammatory signaling in the
CECs of the vasculature, followed by the activation of microglia.

Cerebral endothelial cells are the earliest sensors in the CNS to the peripheral
inflammation
After identifying that the CECs in the brain respond earlier than microglia during
acute systemic inflammation, we wanted to confirm the RNA-seq data and further
identify the role of astrocytes as well as pericytes to get a simultaneous global picture of
any contribution from these other two cell types covering the cerebral vessels. RT-qPCR
for the gene expression of the FACS- sorted samples collected earlier confirmed the
initial activation of early response genes Egr1, Nr4a1, Ier3, Dusp1, Fos, Atf3, Egr3, Jun,
Junb, Fosb, Ier2, Hspa1a1 (Figure 3-31A through F, J through O) in CECs compared to
the other cell types microglia, astrocytes and pericytes. Of note, the genes Tnf, Tnfaip3
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Figure 3-27. MA plots showing the pairwise comparisons between sorted cerebral
endothelial cells and microglia at each time point post LPS treatment.
A through C. MA plots of the pairwise comparisons after LRT test using reduced model
in DESeq2, in CECs compared to microglia at timepoints (A) 30 minutes, (B) 1 hour and
(C) 2 hours. log fold changes (LFCs) are plotted against the mean of normalized counts
to determine the variance between two treatments in terms of gene expression. Red nodes
on the graph represent statistically significant data points i.e. p.adj < 0.05 and LFC > 1.5.
Gray nodes are data points that are not statistically significant. Numerical values in
parentheses for the significant legend indicate the number of genes that meet the prior
condition Dashed lines indicate the cutoff LFC values, n= 3 (males) each group.
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Figure 3-28. Gene ontology enrichment plots showing the pairwise comparisons
between sorted cerebral endothelial cells and microglia at each time point post LPS
treatment.
A through C. GO enrichment dot plots showing the number of genes affected in top 10
enriched inflammation related GO terms (A) at LPS 30 minutes in CECs compared to
LPS 30 minutes microglia (B) at LPS 1 hour in CECs compared to LPS 1 hour microglia
(C) at LPS 2 hours in CECs compared to LPS 2 hours microglia, n= 3 (males) each
group.
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Figure 3-29. Heatmap of the genes related to the regulation of vascular tone in
cerebral vessels at 1-hour post LPS treatment.
Heatmap showing the significant genes belonging to gene ontology terms regulation of
blood vessel diameter (GO:0097746), cell junction disassembly (GO:0150146), negative
regulation of cell adhesion (GO:0007162), basement membrane organization
(GO:0071711) in CECs from the LPS treatment time point 30 minutes (significant genes
(p.adj < 0.05 and LFC > 1.5) in CECs LPS 30 minutes compared to CECs PBS); n= 3
(males) each group.
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Figure 3-30. Effects of systemic inflammation on endothelial barrier integrity in
sorted and microglia and cerebral endothelial cells.
A. Heatmap showing the changes in significant genes belonging to gene ontology terms
establishment of endothelial barrier (GO:0061028) and endothelial cell apoptotic
processes (GO:0072577), in microglia and CECs at LPS treatment time point 2 hours
(significant genes (p.adj < 0.05 and LFC > 1.5) in CECs LPS 2 hours compared to CECs
PBS), B. GO enrichment dot plots showing the number of genes affected and the top 10
enriched endothelial barrier related GO terms in the CECs at LPS 2 hours compared to
PBS, n= 3 (males) each group.
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Figure 3-31. Cerebral endothelial cells are the earliest to respond to the peripheral
inflammation in the CNS.
A through O. Time course of mRNA fold change in microglia, astrocytes, CECs and
pericytes isolated from the brains of mice injected with 10mg/kg LPS (A) Egr1, (B)
Nr4a1, (C) Ier3, (D) Dusp1, (E) Fos, (F) Atf3, (G) Tnf, (H) Tnfaip3, (I) Irak2, (J) Egr3,
(K) Jun, (L) Junb, (M) Fosb, (N) Ier2, and (O) Hspa1a1. Graphs depict mean ± SEM, n=
4 (males) each group, Two-way ANOVA with Dunnett post-hoc test, *p<0.05, **p<0.01,
***p<0.001. Asterisks indicate significance at that particular treatment time point as
compared to the respective PBS group in each of the cell types. The comparison between
the cell types at each of the time points also yielded few significant results but were not
depicted.
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and Irak2 in NF-κB pathway also displayed the earliest changes in CECs compared to the
rest (Figure 3-31G through I). This further validated our findings from the earlier RNAseq. Additionally, we did not detect CD45 high macrophage infiltration in the CNS up to
4 hours after peripheral LPS insult (Supplementary Figure 3-32A through E), suggesting
that the earlier changes to BBB were nondisruptive and its disruption followed by
leakage is a later event to that of the initial CEC activation. Together, these results
suggest that the CECs are activated and contribute to inflammatory signaling initially in
the CNS, well before the functional effects on the BBB happen.

Discussion
This study reports that the systemic inflammation begins to exert its effects on the
cerebral vasculature as early as five minutes. Furthermore, such activation was observed
only in the cerebral endothelial cells, suggesting their role in the propagation of
peripheral inflammatory responses into the CNS. CECs displayed the earliest changes in
transcription of pro-inflammatory mediators and cytokines in the CNS and are most
likely the cells primarily responsible for the initiation of neuroinflammatory cascade. To
our knowledge, ours is the first in-vivo study providing comprehensive transcriptional
insights into the immediate effects on the cerebral vasculature as well as on the vascular
and glial cells in the CNS during acute systemic inflammation. The acute transcriptional
profiles in the cerebral vasculature were characterized by isolating the cerebral vessels
after the induction of systemic inflammation using bacterial lipopolysaccharide (LPS)
and show that the isolated cerebral vessels display changes in proinflammatory genes
during systemic inflammation. By doing an acute time course study, the cerebral
vasculature was shown to respond as early as 5 minutes by upregulating the immediate
early genes followed by the activation of NF-κB signaling. To know the cell type specific
contribution in the CNS during the initial progression of SAE, a method for
simultaneously isolating the gliovascular cells from an adult mouse brain using
multicolor flow cytometry was initially validated. The cerebral endothelial cells were
then found to be activated immediately following systemic inflammation. Furthermore,
microglial activation was found to occur after CEC activation by simultaneous
comparison of the gene expression patterns in both cell types in a time course manner
after the induction of systemic inflammation. Together, these results showed that the
cerebral endothelial cells are the earliest sensors of peripheral inflammation and rapidly
relay the peripheral inflammatory status into the CNS during the progression of SAE.
IEGs have an essential role in the acute immune responses and are transcribed within
minutes of cell-extrinsic signals without the need of de-novo protein synthesis [118, 124].
These results showed the prompt upregulation of immediate early genes as well as
changes in the genes related to blood vessel morphology, activation of NF-κB pathway
and Tnf production in the isolated cerebral vessels, all indicating towards the immediate
and rapid effects of systemic inflammation on cerebral vasculature.
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Figure 3-32. Microglia and macrophage populations in the brain during systemic
inflammation.
A. Flow cytometry gating strategy of brain CD45 high CD11b+ (indicated by red gates)
and CD45 low-mid CD11b+ (indicated in brown gates) myeloid cells from the mice
injected with 10mg/kg LPS and sacrificed at various time points, Mice injected with LPS
(1mg/kg) once daily for four days consecutive days and sacrificed 24 hours after the last
injection are used as positive control (Pos control), B through E. Quantitation of brain (B,
C) CD45 high CD11b+ and (D, E) CD45 low-mid CD11b+ as a percent of total CD45
and total live cells. Graphs depict mean ± SEM, n= 4 (males) each group, One-way
ANOVA with Dunnett’s post-hoc test, *p<0.05, **p<0.01, ***p<0.001.
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Neuroinflammation resulting from glial cell activation is a characteristic phenomenon
in acutely progressing CNS conditions like SAE which further leads to delirium and
sickness behavior [24, 125, 126]. Microglial activation causes reactive astrogliosis, which
progresses to a widespread neuroinflammation [102]. Microglia, the resident myeloid
cells in the CNS have toll like receptors to sense pathogen associated molecular patterns
[127], but there is an absence of a direct infection in the CNS during SAE [18]. The BBB
is reported to remain intact anatomically until 4 hours of the initiation of the peripheral
inflammation [128] which do not allow the passage of circulating LPS and peripheral
cytokines into the CNS until then [129], excluding the circumventricular organs (CVOs)
which lack BBB. However, even in the CVOs, the initial changes are detected near the
blood vessels [5, 114, 130, 131]. Recent study revealed the effect of microglial activation
on BBB integrity during neuroinflammation [132]. The precise mechanism of the initial
microglial activation and the induction of neuroinflammation in-vivo are still elusive.
Thus, it is important to know the sequence of molecular events happening during the
initial inflammatory progression into the CNS, the identity of the cell type/s initially
affected, and the inflammatory signaling mechanism responsible for initiating microglial
activation which results in further damage of BBB alongside widespread
neuroinflammation.
Not only microglia and astrocytes, but also the cells of cerebrovascular system, i.e.
CECs and pericytes were found to respond to peripheral inflammation. However, it is
important to know if such an effect on the CECs is due to the initiation of
neuroinflammation induced by microglial activation or whether it is an independent
effect of peripheral inflammation which could further lead to neuroinflammation. From
my results, it can be concluded that the cerebral vasculature senses the peripheral
inflammatory signals and responds by the rapid induction of IEG expression, specifically
in the CECs. The CECs were then found to display rapid changes in the genes regulating
vascular tone following systemic inflammation, together explaining that these changes
might contribute to the microcirculatory dysfunction at cellular levels [133] seen in the
cerebral blood vessels. Simultaneously, inflammatory signaling was rapidly induced by
the activation of NF-κB pathway and upregulation of Tnf production earlier in CECs
followed by microglia. Notably, these results demonstrate that the microglia are activated
later than that of CECs indicating that the CECs are the earliest sensors of peripheral
inflammation in the CNS, and initial triggering of microglial activation might be due to
the proinflammatory factors secreted by the activated CECs. Following the initial CEC
activation and inflammatory signaling, microglial activation occurs, leading to further
increase in the expression of proinflammatory cytokines. Finally, the activation of
endothelial cell apoptotic signaling and alteration of BBB occur, which together lead to
apoptotic cascade in CECs, affecting the barrier integrity. Heparan fragments released
from the degrading endothelium glycocalyx during sepsis are found to sequester brain
derived neurotrophic factor and impair the hippocampal long term potentiation [134,
135]. Taken together, these results modeled the sequential events during the advancement
of systemic inflammation into the CNS, clearly demonstrated that the CECs are the
earliest sensors which rapidly respond to and relay the peripheral inflammatory status
into the CNS during the progression of SAE.
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Systemic inflammatory factors affecting the brain are relevant in acutely progressing
CNS disorders like encephalopathies and also are involved in the development of chronic
neurodegenerative conditions like Alzheimer’s disease [8, 136]. The ongoing pandemic
of COVID-19 caused by SARS-CoV-2 also leads to acute necrotizing hemorrhagic
encephalopathy [137]. Our results provide insight into the mechanism of progression of
peripheral inflammatory responses into the CNS as well as a glimpse into the timing for
initiation of microglial activation which lead to neuroinflammation. These findings as
such are applicable to peripheral inflammation induced neurological complications where
in there is no direct CNS infection [138] but primarily develop due to the prevailing
systemic inflammatory responses [137, 139]. Our finding that the peripheral
inflammatory factors initially affecting the CECs could be more relevant in the context
that CEC function can be modulated by systemically administered drugs to block the
progression of peripheral inflammation into the CNS. Modulation of CEC activation
earlier during the course of SIRS may thus represent a newer therapeutic target to
possibly inhibit inflammatory signaling in CECs to halt neuroinflammation and BBB
disruption during SAE. Furthermore, therapeutic targeting of CECs may not require the
drugs to pass BBB and as such overcomes a major hurdle in CNS drug delivery.
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CHAPTER 4. ROLE OF PERIPHERAL CIRCULATING EXOSOMES IN
MEDIATING NEUROINFLAMMATION DURING SYSTEMIC
INFLAMMATORY CONDITIONS

Introduction
Intercellular communication is crucial for the immune cells to transfer inflammatory
signals across the whole body [73]. Cytokines, chemokines, and cell surface receptors
play an important role in mediating such mechanisms. In addition to these mediators,
recent evidence suggests that immune cells can also coordinate inflammatory responses
by secreting nano-sized lipid packages termed as exosomes, which carry a variety of
biomolecules including proteins, lipids and nucleic acids that can be taken up by the
recipient cells [74-77]. Exosomes are a homogenous population of EVs ranging in size
from 30nm to 100nm and are encapsulated by a lipid bilayer [77, 79].
Exosomes mediate cell to cell communication after they initially attach or fuse with a
recipient cell membrane and are then internalized by the mechanism of endocytosis [84,
85]. Despite their obvious homogeneous size, exosomes mediate a broad spectrum of
effects on the recipient cells indicating that different types of cells surrounded by varying
physiological microenvironments, release different kinds of exosomes characterized by
heterogeneity in their molecular profile [81]. One of the earlier studies on exosomal cargo
transport describes the reporter gene expression in brain cells as a result of functional
transfer of exosomal cre recombinase, followed by the translation of cre RNA in purkinje
neurons [140]. Their results show that blood derived exosomes transmit functional RNA
to cells of various tissues including the purkinje neurons in the central nervous system
(CNS). This phenomenon, though rare under normal homeostatic conditions, could
become highly efficient under peripheral inflammatory conditions. Purkinje neurons
which received blood derived exosomal RNA, also displayed changes in the miRNA
profile suggesting the involvement of miRNA in such a mechanism [140].
The role of immune system activation on the brain in the context of inflammation is
highly relevant for most of the neurodegenerative diseases and yet the mechanisms that
underlie these interactions are poorly understood and needs to be elucidated in detail. As
exosomes mediate intercellular immune signals in the periphery, they could possibly play
a role in transmitting the same to the CNS and thus it is imperative to study the role of
exosome mediated peripheral and CNS communication in detail and learn their overall
contribution in causing neuroinflammation.
The potential role of peripheral circulating exosomes in mediating neuroinflammation
was thus studied by inducing systemic inflammation by LPS and then isolating the
exosomes from the serum collected from the LPS or PBS treated mice [141].
Downstream experiments were then performed using these serum derived exosomes to
study their potential to induce neuroinflammation.
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Results

LPS induces widespread microgliosis
LPS response is dependent on the age and genetic background of the mice strains
being tested as well as on the source and purity of LPS [60, 61]. In addition, the dose and
dosage regimen, and the site of injection also have a profound effect on the systemic
inflammation evoked by LPS treatment in the recipient mice [63, 64]. Since the literature
has a lot of ambiguity on LPS responses [67], the LPS responses to neuroinflammation
were initially evaluated. Systemic administration of LPS evokes a rapid transcriptional
activation of proinflammatory genes both in peripheral tissues as well as in CNS [64,
142, 143]. Our experiments also showed increased activation in microglia as evidenced
by increase in the expression of IBA1 (Ionized calcium binding adaptor molecule 1) and
F4/80 (also known as EMR1, EGF-like module-containing mucin-like hormone receptorlike 1), after a single intraperitoneal LPS injection in 2-3 months old male mice (Figure
4-1) consistent with the earlier published literature [65, 67].
Characterization of the isolated exosomes1
To characterize the isolated exosomes, the serum derived exosomes were probed for
the presence of exosomal markers and for their size distribution. Exosomes were isolated
from the control or treated mice after a single intraperitoneal injection of either PBS or
LPS at 5mg/kg respectively and sera ware collected 24 hours post injection. Isolated and
purified exosomes derived from the serum of control and LPS treated mice were analyzed
for exosomal marker protein enrichment and vesicular size distribution. Enrichment of
marker protein TSG101 as well as ALIX was observed in the purified exosomal fraction
compared to the supernatant (Figure 4-2A). Additionally, the cellular marker beta actin
was not detected in the exosomal fraction, suggesting the absence of cellular
contamination (Figure 4-2B). Ultracentrifugation (UC) is the most frequently used
method for the isolation of exosomes from plasma/serum. However, isolation of
exosomes by performing ultracentrifugation for large numbers of samples is technically
challenging, labor-intensive as well as time-consuming. Furthermore, there are several
concerns on the efficiency and purity of isolating exosomes using UC [144]. Compared to
UC, polymeric precipitation techniques are much faster and easier, though this method
also has certain limitations [145, 146]. The size and zeta potential of the exosomal
fraction isolated using the polymeric precipitation-based kit (Exoquick kit, System
Biosciences) was compared to the exosomal fraction isolated by the classic differential
ultracentrifugation method. It was found that both methods yielded exosomes with Zeta
potential around − 10 mV, which was within the ideal range of − 8 ~ − 12 mV, suggesting

1

This section and the next are modified from final submission with open access permission. Li, J.J., Wang,
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Figure 4-1.

LPS induces widespread microgliosis.

A, B. Images of the hippocampal area from the brains of the mice intraperitoneally
injected with either PBS or LPS. Brain sections were stained with anti-IBA1 (Ionized
calcium binding adaptor molecule 1) antibody for microglia (red) and with anti-F4/80
(also known as EMR1, EGF-like module-containing mucin-like hormone receptor-like 1)
antibody for microglia (green). DAPI was shown in blue. Graphs include comparison of
the relative immunofluorescent intensity of IBA1 in the (A) cortex and (B) hippocampus
between the treatments, n = 3 per group. Data represents mean ± SEM.
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Figure 4-2.

Characterization of the isolated exosomes.

A. Western blot image showing enriched exosomal markers ALIX (ALG-2 interacting
protein X, 96 kda) and TSG101 (Tumor susceptibility gene 101, 45 kda) expression in the
exosomal preparation compared to supernatant B. Western blot image showing absence
of beta actin (42 kda) expression in the exosomal preparation Sup - supernatant, EXO exosomal preparation, WCL - whole cell lysate. C, D. Size and Zeta potential of
exosomes purified from the sera of mice treated with PBS or LPS either by Exoquick kit
or by differential ultracentrifugation (UC), n = 3 per group. E. Percentage of exosomes in
the size range of 10–200 nm, Data represents mean ± SEM; ns indicates no statistical
significance, *P < 0.05, ***P < 0.001, as compared to the PBS group. Figure panel A is
modified from final submission with open access permission. Li, J.J., Wang, B., Kodali,
M.C. et al., In vivo evidence for the contribution of peripheral circulating inflammatory
exosomes to neuroinflammation. J Journal of Neuroinflammation, 2018. 15(1): p. 8.
https://doi.org/10.1186/s12974-017-1038-8 [141].
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that the precipitation-based method did not alter the property of exosomes compared to
the UC method. LPS treatment did not cause any change in zeta potential, however,
treatment with LPS (10 mg/kg for 6 hours) slightly, but significantly, increased the
percentage of exosomes that are between 10 and 200 nm. The average size of exosomes
was not significantly different between the groups. These results indicated that the
Exoquick exosome precipitation kit was sufficient, as well as a simple and cost-effective
method to purify exosomes from mouse serum. Thus, exosomes were isolated using the
polymeric precipitation-based exosome isolation kit in this study in all further
experiments.

Isolated exosomes are not contaminated with endotoxin after precipitation from
serum
CD14 attaches with TLR4 and becomes the cellular pattern recognition receptor for
LPS. TLR4 is the transmembrane signal-transducing domain in the CD14/TLR4 receptor
complex [55]. LPS induced CD14/TLR4 signaling is markedly enhanced by the presence
of LPS binding protein (LBP) which can also bind to LPS and elevate the production of
inflammatory cytokines TNF-α and IL-1β [58] by transferring the bound LPS to CD14.
LBP is synthesized predominantly in the liver as an acute-phase protein, and its plasma
concentration is upregulated exponentially during acute inflammatory responses [57]. As
we precipitated the exosomes from the serum in our study, it is possible that the isolated
exosomal fraction could have been contaminated with circulating LPS bound to LBP,
which can cause incorrect interpretation of the results. Thus, the levels of LPS were
measured using the Limulus Amebocyte Lysate (LAL) assay. Endotoxin test results
indicated that these exosomes isolated from mice at 1, 4, or 24 hours after LPS injection
had barely detectable endotoxin contamination, whereas the sera from these mice
contained 194.80 ± 18.53 endotoxin units/ml (EU/ml) and 204.61 ± 12.47 EU/ml at 1 and
4 h after LPS injection, respectively. The endotoxin level in sera dropped to 29.98 ± 1.67
EU/ml at 24 h after the injection., suggesting that the exosomal fraction is not
contaminated by LPS co-precipitation (Figure 4-3A).

Systemic inflammatory conditions increase exosome secretion as well as total
exosomal protein content
To know if the exosome secretion is altered during systemic inflammation, we
determined the total protein content of the exosomes isolated from the sera of the mice
which were earlier injected with LPS or PBS. Our results suggested that exosome
secretion is indeed increased after LPS injection (Figure 4-3B), suggesting the effect of
systemic inflammation on exosome secretion. Furthermore, by quantifying the total
protein amounts of the exosomes isolated from the serum of the mice after LPS or PBS
injection, we also found the increase of total protein content of the exosomes (Figure
4-3B).
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Figure 4-3. Isolated exosomes are not contaminated with endotoxin after
precipitation from serum.
A. Endotoxin levels in exosome suspension or serum from PBS- or LPS-treated mice.
Sera were collected from mice 1, 4, or 24 h after intraperitoneal LPS injection. n = 3–4
per group, Kruskal-Wallis test, Dunn’s post-hoc test, *p<0.05, **p<0.01, ***p<0.001.
B. Total protein concentration of intact and lysed exosomes isolated from the sera of the
mice injected with LPS or PBS for 24 hours. n = 3-4 per group, Data represents
mean ± SEM; ***P < 0.001 as compared to the PBS. Figure Panel B is modified from
final submission with open access permission. Li, J.J., Wang, B., Kodali, M.C. et al., In
vivo evidence for the contribution of peripheral circulating inflammatory exosomes to
neuroinflammation. J Journal of Neuroinflammation, 2018. 15(1): p. 8.
https://doi.org/10.1186/s12974-017-1038-8 [141].
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Serum derived exosomes purified from LPS-challenged mice activate microglia,
astrocytes, and cerebral microvascular endothelial cells
To investigate the neuroinflammatory potential of peripheral circulating exosomes
during systemic inflammation, serum derived exosomes purified after LPS challenge
(SDEL) were used. Exosomes were isolated from serum of the mice which were injected
with either PBS or LPS 24 hours earlier (Figure 4-4). Cultured BV2, C8-D1A and
Bend.3 cells were then incubated with the isolated exosomes, as well as the supernatant
from the exosomes precipitated from the mice treated with LPS (Figure 4-5A). Our
results revealed that the exosomes derived from the mice injected with LPS, but not PBS
increased the expression of proinflammatory cytokine genes in the treated cells (Figure
4-5B). Additionally, the supernatant from the exosome precipitation of sera derived from
the mice injected with LPS, did not induce an inflammatory response in the cells.

Serum derived exosomes purified from LPS-challenged mice increase
proinflammatory gene expression in the brain
Exosomes isolated from sera of the mice that were injected with either PBS or LPS 24
hours earlier were injected to recipient mice via tail vein. Brains were then isolated from
the recipient mice 24 hours after the tail vein injection and analyzed for the expression of
proinflammatory genes. Proinflammatory cytokines Il1b, Tnf, chemokine genes Ccl2,
Ccl5 and pan reactive gene Lcn2 were found to be upregulated in the brains of the mice
injected with the exosomes isolated from the sera of LPS injected mice but not PBS
injected mice (Figure 4-6).

Intravenously administered serum-derived exosomes purified from LPS-challenged
mice induce microglial and astrocytic activation in the CNS2
To know if the exosomes can induce neuroinflammation, the exosomes isolated from
the sera of the mice treated with LPS or PBS were injected via tail vein into the recipient
mice, and the brains were collected 24 hours later. Histological staining for IBA1 in the
recipient mice was performed to examine the microglial response in the hippocampal and
neocortical areas. Exosomes purified from mice treated with 5mg/kg LPS for 24 hours,
but not PBS significantly increased microglial activation in the recipient mice after 24
hours (Figure 4-7A). Similar observations were made in the astrocytic response in the
hippocampal regions, as indicated by the glial fibrillary acidic protein (GFAP)
fluorescence intensity (Figure 4-7B).
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This section and the next are modified from final submission with open access permission. Li, J.J., Wang,
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exosomes to neuroinflammation. J Journal of Neuroinflammation, 2018. 15(1): p. 8.
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Figure 4-4. Scheme depicting the in experimental design for investigating the
effects of serum derived exosomes.
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Figure 4-5. Serum derived exosomes purified from LPS-challenged mice activate
microglia, astrocytes, and cerebral microvascular endothelial cells.
A. Scheme depicting the in vitro experimental design for investigating the effects of
serum derived exosomes. B through E. mRNA fold change levels of various
proinflammatory genes in the cell lines BV2, C8-D1A and Bend treated for 24 hours with
0.1 mg/ml of exosomes derived from the sera of the donor mice (PBS Exo or LPS High
Exo), or with the supernatant obtained after exosome precipitation from the sera of LPS
treated mice (LPS High SN). Donor mice were earlier treated with either PBS or LPS
5mg/kg for 24 hours, and exosomes were isolated from the sera, in addition supernatant
obtained after exosome isolation from the sera of mice treated with LPS was also used,
(B) Il1a, (C) Tnf, (D) Il6, (E) Il1b (n= 3-4 male mice in each group, Two-way ANOVA
with Dunnett post-hoc test, *p<0.05, **p<0.01, ***p<0.001).
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Figure 4-6. Serum derived exosomes purified from LPS-challenged mice increase
proinflammatory gene expression in the brain.
A through E. mRNA fold change levels of various proinflammatory genes in the brains
of the mice treated for 24 hours after the intravenous injection (via tail vein) of 1 mg
exosomes (in 200μl PBS) isolated from the sera of donor mice (PBS Exo or LPS High 24
hr Exo). Donor mice were earlier treated with either PBS or LPS 5mg/kg for 24 hours,
and exosomes were isolated from the sera. (A) Tnf (B) Il1b, (C) Ccl2, (D) Ccl5 (E) Lcn2,
(n= 3-4 male mice in each group, Mann-Whitney test, not significant).
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Figure 4-7. Intravenous administration of serum-derived exosomes purified from
LPS-challenged mice induce microglial and astrocytic activation in the CNS.
A, B Exosomes isolated from LPS-treated mice increase microglial and astrocytic
activation after intravenous (IV) tail vein infusion. Images of the hippocampal area from
C57BL/6J mice. Mice were treated for 24 hours after the intravenous injection (via tail
vein) of 1 mg exosomes (in 200μl PBS) isolated from the sera of donor mice (Saline Exo
or LPS 5mg Exo). Donor mice were earlier treated with either PBS or LPS 5mg/kg for 24
hours, and exosomes were isolated from the sera. Brain sections were stained with (A)
anti-IBA1 antibody for microglia (red) or (B) with anti-GFAP antibody for astrocytes
(green) and with DAPI for nuclei (blue). Quantification of the relative
immunofluorescent intensity of IBA1 or GFAP in the hippocampal area in Saline-Exo
(Exosomes derived from the sera of the mice which were earlier injected with
intraperitoneal PBS for 24 hours) and LPS 5mg/kg Exo (Exosomes derived from the sera
of the mice which were earlier treated with intraperitoneal LPS 5mg/kg for 24 hours)
treated mouse brains. Mann-Whitney test, *p<0.05, **p<0.01, ***p<0.001 Data
represent mean ± SEM. Modified from final submission with open access permission. Li,
J.J., Wang, B., Kodali, M.C. et al., In vivo evidence for the contribution of peripheral
circulating inflammatory exosomes to neuroinflammation. J Journal of
Neuroinflammation, 2018. 15(1): p. 8. https://doi.org/10.1186/s12974-017-1038-8 [141].
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Intracerebroventricular infusion of serum-derived exosomes purified from
LPS-challenged mice induce microglial and astrocytic activation in the CNS
Upon transfusion via tail vein, exosomes isolated from mice challenged with LPS
induced microglial and astrocytic activation compared to the exosomes isolated from
PBS injected mice. However, this does not prove if the exosomes travelled directly to the
CNS to cause neuroinflammation as they could elicit an inflammatory response in the
periphery and cause subsequent neuroinflammation. To provide further evidence for a
direct causative role of peripheral exosomes to CNS inflammation, we injected the SDEL
into normal mice via intracerebroventricular route and then determined the
neuroinflammation 24 hours later. The intracerebroventricularly infused exosomes
isolated from LPS-challenged donor mice markedly increased neuroinflammation with
increased IBA1 expression in microglia (Figure 4-8A) as well as GFAP expression in
astrocytes (Figure 4-8B).

Discussion
This study investigated a novel mechanism of peripheral contribution to
neuroinflammation mediated by circulating exosomes. Initially the microglial and
astrocytic activation in the brain was demonstrated by using the peripheral LPS induced
neuroinflammation model which is consistent with many other reports [67]. Next, the role
of serum derived exosomes was investigated to know if they can cause
neuroinflammation during acute systemic inflammation induced by a single
intraperitoneal LPS injection.
To confirm the extracellular vesicles that were isolated from the serum of the mice, we
characterized the size and the zeta potential and found them to be the same as that of the
average size of exosomes. We also confirmed the exosomes by detecting the
characteristic exosomal markers ALIX and TSG101 [81, 147] in the isolated exosomal
fraction, but not in the supernatant. Furthermore, we also did not detect the contamination
with the blood cells, as evidenced by the absence of beta actin in the isolated exosomal
fraction. This characterization of isolated exosomes suggests that they are of required size
and identity of exosomes. Additionally, endotoxin contamination was not detected in the
isolated exosomes. This further proves that the effects we saw in the further experiments,
are indeed due to exosomes themselves, but not due to contamination with bacterial
endotoxin. The finding of increased exosome protein concentration as determined by
intact as well as lysed protein quantification of exosomal fractions after LPS injection
suggests that there is an increase in the number of secreted exosomes and also points
towards the alteration in the exosomal content and cargo during systemic inflammatory
conditions, indicating a possible role of exosomes in mediating intercellular
communication during inflammatory conditions.
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Figure 4-8. Intracerebroventricular infusion of serum-derived exosomes purified
from LPS-challenged mice induce microglial and astrocytic activation in the CNS.
A, B Exosomes isolated from LPS-treated mice increase microglial and astrocytic
activation after intracerebroventricular (ICV) infusion. Images of the hippocampal area
from C57BL/6J mice. Mice were treated for 24 hours after the intracerebroventricular
infusion of exosomes isolated from the sera of donor mice (Saline Exo or LPS 5mg Exo).
Donor mice were earlier treated with either PBS or LPS 5mg/kg for 24 hours, and
exosomes were isolated from the sera. Brain sections were stained with (A) anti-IBA1
antibody for microglia (red) or (B) with anti-GFAP antibody for astrocytes (green) and
with DAPI for nuclei (blue). Quantification of the relative immunofluorescent intensity of
IBA1 or GFAP in the hippocampal area in Saline-Exo (Exosomes derived from the serum
of the mice which were earlier injected with intraperitoneal PBS for 24 hours) and LPS
5mg/kg Exo (Exosomes derived from the serum of the mice which were earlier treated
with intraperitoneal LPS 5mg/kg for 24 hours) treated mouse brains. Mann-Whitney test,
*p<0.05, **p<0.01, ***p<0.001 Data represent mean ± SEM. Modified from final
submission with open access permission. Li, J.J., Wang, B., Kodali, M.C. et al., In vivo
evidence for the contribution of peripheral circulating inflammatory exosomes to
neuroinflammation. J Journal of Neuroinflammation, 2018. 15(1): p. 8.
https://doi.org/10.1186/s12974-017-1038-8 [141].
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Exosomes derived from the sera of mice challenged with LPS caused significant
upregulation of proinflammatory genes Il1b, Tnf, Il6 and 1l1a in cultured BV2, C8-D1A
and Bend.3 cells, demonstrating the inflammatory potential of the exosomes during
systemic inflammation. More interestingly, the supernatant obtained after the
precipitation of exosomes was not able to induce such effect, suggesting that the
exosomes mediate such functional effects in the recipient cells during inflammatory
conditions and communicate with the distant cells. Furthermore, these exosomes when
injected via tail vein lead to an increase in the proinflammatory cytokine genes Tnf, Il1b,
chemokine genes Ccl2, Ccl5, and pan reactive gene Lcn2. This suggests that the
exosomes might be able to carry proinflammatory cargo from the periphery into the CNS
and further stimulate inflammation. However, this could also be due to the peripheral
immune responses to the injected exosomes, which can also further cause
neuroinflammation. Additionally, the exosomes derived from the sera of the mice
injected with LPS but not PBS were able to cause a significant widespread microgliosis
as well as astrogliosis. To further confirm that this neuroinflammation was indeed
mediated by exosomes, we also injected the exosomes via intracerebroventricular route.
This also displayed the prominent activation of microglia as well as astrocytes only in the
mice that were treated with exosomes derived from the donor mice challenged with LPS,
but not with PBS.
Taken together these results suggest that peripheral circulating exosomes during
systemic inflammatory conditions can undergo alteration in their content and are further
capable of reaching the CNS to induce the upregulation of proinflammatory cytokines,
and also activate microglia and astrocytes and finally cause neuroinflammation.
However, it is important to know the role of choroid-plexus epithelium and blood
brain barrier endothelium in mediating the transport of SDEL from the periphery and the
CNS. Recently it is shown that epithelial cells of the CP sense and relay the peripheral
inflammatory status to the CNS by releasing the extracellular vesicles into the CSF,
which transfer this pro‐inflammatory message to recipient brain cells [148]. Nevertheless,
it is still unclear if the peripheral inflammatory exosomes has any preference in mediating
this effect on the CP epithelial cells compared to BBB endothelial cells, and if the
exosomes released by the peripheral immune cells travel into the CNS via the CP and/or
BBB.
This study is based on inducing an acute model of systemic inflammation using LPS
at 5mg/kg for 24 hours. LPS is widely characterized and reproducible endotoxemia
model causing whole body systemic inflammation and global CNS neuroinflammation
[67]. It should be noted that this might not accurately represent the chronic inflammatory
conditions observed during inflammation associated systemic disease progression or
ageing associated neuro degenerative conditions. However, the aim was to recapitulate
the inflammatory conditions at a steady yet rapid rate in order to get a broader overview
of the potential mechanism of such a response in the periphery and CNS. Thus, future
studies using chronic models can aim to provide more clear insight on peripheral
circulating exosome mediated induction of neuroinflammation. Some of the challenges
on the technical side of this project include the exosomal isolation. Using a precipitation
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kit for the isolation of exosomes seems the most plausible alternative to
ultracentrifugation to achieve a homogenous population of exosomes. At this time, it is
difficult to achieve quantitative conclusions by employing currently available exosome
quantification methods but could possibly aid in a qualitative perception on the tissue
specific effects. Nevertheless, despite these hurdles, this study generates a fundamental
understanding of exosome mediated peripheral and CNS communication.
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CHAPTER 5.

CONCLUSIONS AND FUTURE DIRECTIONS

Dissection of Molecular Sequalae Temporally in the Brain During the Progression
of SAE Reveals That the Cerebral Endothelial Cell Activation Is the Earliest Event
and It Precedes Microglial Activation
The study presented in (Chapter 3) facilitates filling our knowledge gap between
peripheral inflammation and microglia-mediated neuroinflammation by identifying CECs
as the early initiators, and microglia as the later drivers for acute neuroinflammatory
cascade.
The following are the areas of significance and novelty:






Detailed transcriptional profiling study on the acute inflammatory responses in
cerebral vessels
Optimized FACS method to isolate all gliovascular cells from mouse brain
Cell-type specific contribution to the transcriptional dysregulation for initiating
neuroinflammatory cascade in the CNS during systemic inflammatory response
syndrome
Comparative study of the gene expression in response to peripheral inflammation
in cerebral endothelial cells and microglia

The following are the principal conclusions:






Cerebral vasculature initially senses the peripheral inflammatory responses as
they propagate into the CNS during systemic inflammation.
CECs of the cerebral vasculature are the earliest responders during acute systemic
inflammation, and in the CNS, they rapidly initiate pro-inflammatory signaling
due to peripheral immune responses.
Microglia are the later responders to that of CECs in the CNS during acute
systemic inflammation
These results model the sequential events during the advancement of systemic
inflammation into the CNS

Taken together these results highlight the mechanism of progression of peripheral
inflammatory responses into the CNS as well as a glimpse into the timing for the
initiation of microglial activation
However, gene expression does not necessarily translate into protein expression and
so, does not directly imply the development of a phenotype. It should be thus noted that
further experiments are warranted to translate our gene expression results to the protein
expression level, in order to find the factors which are initially released by CECs and
could represent a possible next step to take forward the conclusions from these findings.
Also, several key questions warrant future investigation as to whether CEC activation
leads to reactive astrogliosis prior to microgliosis, and which factors released by CECs
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can cause microglial or astrocytic activation. Astrocytes require Tnfr1 for inflammatory
response [149] and are activated to neurotoxic A1 phenotype by TNF [102]. Since our
results show that the CECs upregulate Tnf earlier, it might possibly lead to activation of
reactive astrocytes surrounding the cerebral vessels, as the astrocytes end feet wrap
around the blood vessels [150]. Nonetheless, whether the CEC activation directly leads to
microglial activation or progresses via an intermediate initial astrogliosis followed by
microgliosis, and then by continuation of such vicious cycle remains to be answered.

Peripheral Circulating Exosomes Contribute to Neuroinflammation During
Systemic Inflammatory Conditions
The study presented in (Chapter 4) presents the novel finding that the serum-derived
exosomes isolated from mice during systemic inflammation induced by LPS, upon their
transfusion into recipient mice via tail vain, markedly increase microglial and astrocytic
activation and increase the expression of inflammatory cytokines in the brain.
These observations suggest that exosomes may serve as an additional way in mediating
the activation of neuroinflammatory processes during systemic inflammatory conditions.
These results help to elucidate the mechanism of communication between the brain
immune surveillance and the peripheral immune system.
The specificity of exosomes in affecting the microglial cells is still unclear. To know
if the exosomes home to which cell types in the CNS besides microglia, it is important to
identify the targeted cell types in CNS which uptake the circulating exosomes during
systemic inflammation and understand the relative affinity of these exosomes towards the
various cells in CNS including neurons, microglia and astrocytes. Increased CNS
expression of pro-inflammatory cytokine mRNAs were observed in the brains of the mice
treated injected with SDEL. However, the cell specific effects of SDEL on the CNS are
still unknown. It is also crucial to identify the effects of circulating exosomes on
microglia as well as the other cell types in CNS which may or may not uptake them
during systemic inflammation. It is also worthwhile to study the role of these exosomes
on the most abundant glial cell, i.e. astrocytes in the absence of microglia, to know if
astrocytic activation is secondary to that of microglial response. Neuroinflammation is
triggered by the intravenous infusion of SDEL. To further validate circulating exosomes
as inflammatory sources in the CNS during systemic inflammation, it is essential to know
if depletion of exosomes during systemic inflammation can ameliorate peripheral
circulating inflammatory exosomes induced neuroinflammation.
Peripheral macrophages adapt to their surrounding microenvironment by a phenotypic
polarization change either towards a pro-inflammatory M1 phenotype that promotes
inflammation or an anti-inflammatory M2 phenotype that leads to anti-inflammatory
response[151, 152]. Both, macrophages[153] as well as microglia[154, 155] are activated
to M1 state by endotoxin stimulation. In the CNS, microglia are also reported to have
similar phenotypic changes associated with neuroinflammation[156, 157]. Future
experiments can be designed to study the role of exosomes in mediating communication
between peripheral macrophage and CNS microglial polarization.
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Though it is demonstrated that the SDEL induce neuroinflammation, it is still unclear
which cell derived exosomes are the major contributors for such an effect. The exosomes
under inflammatory conditions have increased pro-inflammatory content and it could be
theorized that these are a major derivative of myeloid lineage. Though macrophages play
a predominant role in inflammatory response, circulating macrophages during
inflammation represent diverse population of subsets derived from bone marrow,
peritoneal cavity and spleen which cause distinct inflammatory responses[158]. Thus, it
is worthwhile to profile and study the molecular signatures i.e. mRNAs, micro RNAs and
circular RNAs of various macrophage derived exosomes during inflammation.
Further studies are required to primarily understand the precise mechanism by which
exosome mediated neuroinflammation occurs, to know which cells in the CNS are the
recipients of peripheral exosomes during systemic inflammatory conditions. It is also
worthwhile to know if exosomal biogenesis associated with miRNA packaging by the
peripheral immune effector cells contributes to the neuroinflammatory signaling cascade
in the CNS
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APPENDIX A. GENE EXPRESSION FOLDCHANGES AND STATISTICS OF INDIVIDUAL PAIRWISE COMPARISONS
FROM RNA-SEQ ANALYSIS

Table A-1.
PBS.
Symbol
Ier3
Fosb
Fos
Nr4a1
Dusp1
Atf3
Egr3
Egr1
Jun
Junb
Ier2
Hspa1a

Supplementary table related to Figure 3-9 listing pairwise comparison statistics in LPS 15 minutes compared to

Gene
ENSMUSG00000003541
ENSMUSG00000003545
ENSMUSG00000021250
ENSMUSG00000023034
ENSMUSG00000024190
ENSMUSG00000026628
ENSMUSG00000033730
ENSMUSG00000038418
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000053560
ENSMUSG00000091971

Basemean
9161.92196
1496.904056
3694.458089
9818.768561
12240.1039
3581.233638
2850.242127
11656.38061
10484.16994
15095.43776
8229.486774
12366.3025

Log2foldchange
2.045728334
2.983667967
3.723838654
3.161392804
3.360882939
3.454395236
2.225509686
2.837737107
2.620189009
3.185924773
2.325638553
4.16665706

Lfcse
0.042339521
0.110027545
0.074136615
0.041494666
0.035206069
0.087102744
0.07258448
0.040269
0.038193465
0.041203035
0.043227307
0.061856728

108

Stat
34.61844367
21.8460566
42.40601815
62.21023243
78.98873657
33.00005376
22.67026886
56.0663819
53.41722801
63.24594288
40.38277394
57.98329758

Pvalue
1.33E-262
8.47E-106
0
0
0
8.11E-239
8.81E-114
0
0
0
0
0

Padj
1.54E-259
5.86E-103
0
0
0
8.85E-236
6.52E-111
0
0
0
0
0

Table A-2.
PBS.
Symbol
Ier3
Fosb
Fos
Nr4a1
Dusp1
Atf3
Egr3
Egr1
Jun
Junb
Ier2
Hspa1a

Supplementary table related to Figure 3-9 listing pairwise comparison statistics in LPS 30 minutes compared to

Gene
ENSMUSG00000003541
ENSMUSG00000003545
ENSMUSG00000021250
ENSMUSG00000023034
ENSMUSG00000024190
ENSMUSG00000026628
ENSMUSG00000033730
ENSMUSG00000038418
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000053560
ENSMUSG00000091971

Basemean
9161.92196
1496.904056
3694.458089
9818.768561
12240.1039
3581.233638
2850.242127
11656.38061
10484.16994
15095.43776
8229.486774
12366.3025

Log2foldchange
3.977240173
6.194236447
5.588559737
4.857440852
3.59612818
6.499963503
5.028212227
5.127535347
3.415445587
4.779297401
3.462289411
6.501814795
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Lfcse
0.041130065
0.105610276
0.073073963
0.040934774
0.035196888
0.084438639
0.06986756
0.039328259
0.037984906
0.040769667
0.042806879
0.061400419

Stat
82.59749062
53.15994502
68.54096228
104.4940626
85.69303503
70.10965051
63.66634564
115.6302227
74.64663962
103.0005316
67.33238898
96.44583708

Pvalue
0
0
0
0
0
0
0
0
0
0
0
0

Padj
0
0
0
0
0
0
0
0
0
0
0
0

Table A-3.
PBS.
Symbol
Ier3
Fosb
Fos
Nr4a1
Dusp1
Atf3
Egr3
Egr1
Jun
Junb
Ier2
Hspa1a

Supplementary table related to Figure 3-9 listing pairwise comparison statistics in LPS 4 hours compared to

Gene
ENSMUSG00000003541
ENSMUSG00000003545
ENSMUSG00000021250
ENSMUSG00000023034
ENSMUSG00000024190
ENSMUSG00000026628
ENSMUSG00000033730
ENSMUSG00000038418
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000053560
ENSMUSG00000091971

Basemean
9161.92196
1496.904056
3694.458089
9818.768561
12240.1039
3581.233638
2850.242127
11656.38061
10484.16994
15095.43776
8229.486774
12366.3025

Log2foldchange
4.089584457
2.863883006
3.906971015
2.202735335
1.904789172
5.400087982
2.166373387
3.745870689
1.711280196
4.091382233
2.220488637
1.210243613

Lfcse
0.041396173
0.11503594
0.075131133
0.043710279
0.036990126
0.085523149
0.075558879
0.04026618
0.039719066
0.04120239
0.044108855
0.069356382
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Stat
84.78040869
19.8536476
44.28218857
37.12479898
35.81466998
56.36003864
20.99519471
78.62356748
28.48204416
85.22277939
37.19182061
9.087031311

Pvalue
0
1.02E-87
0
1.12E-301
6.53E-281
0
7.26E-98
0
1.96E-178
0
9.25E-303
1.02E-19

Padj
0
2.90E-86
0
7.59E-300
4.15E-279
0
2.20E-96
0
8.67E-177
0
6.32E-301
1.31E-18

Table A-4.
Symbol
Tnfaip3
Nfkbia
Tnf
Il1b
Ppbp
Cxcl1
Ptgs2
Cxcl10
Ccl12
Gch1
Cnr1
Zfp36
Jun
Junb
Cxcl2
Jund

Supplementary table related to Figure 3-10.
Gene
ENSMUSG00000019850
ENSMUSG00000021025
ENSMUSG00000024401
ENSMUSG00000027398
ENSMUSG00000029372
ENSMUSG00000029380
ENSMUSG00000032487
ENSMUSG00000034855
ENSMUSG00000035352
ENSMUSG00000037580
ENSMUSG00000044288
ENSMUSG00000044786
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000058427
ENSMUSG00000071076

Basemean
9466.877995
24691.37012
274.3510962
830.013287
120.4146146
28342.61911
32813.74795
51363.8536
349.1488707
2429.995259
278.7260238
18255.99707
10484.16994
15095.43776
8389.878604
7427.17751

Log2foldchange
1.432211715
1.236751616
4.285165149
2.057303438
-1.629218759
5.802165293
1.234618234
1.080808763
2.00887161
0.799302317
1.071906948
3.341359257
2.620189009
3.185924773
4.944605366
0.76557607

Lfcse
0.056321332
0.03187299
0.482703364
0.248011252
0.184677288
0.139105469
0.044135262
0.142671141
0.264832184
0.06469625
0.147879605
0.036813804
0.038193465
0.041203035
0.287604769
0.038076102
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Stat
15.13124206
20.60527154
7.675863536
5.956598438
-5.681363261
37.54104939
14.83209127
3.510231704
5.395385057
3.389722217
3.326401551
75.00880081
53.41722801
63.24594288
15.17570579
4.873820074

Pvalue
1.01E-51
2.46E-94
1.64E-14
2.58E-09
1.34E-08
0
9.09E-50
0.000447716
6.84E-08
0.000699635
0.000879751
0
0
0
5.12E-52
1.09E-06

Padj
4.02E-49
1.55E-91
2.38E-12
2.55E-07
1.25E-06
0
3.49E-47
0.022690504
6.03E-06
0.033655518
0.041266687
0
0
0
2.08E-49
8.16E-05

Table A-5.
Symbol
Icosl
Ccl3
Hspb1
Mcoln2
Slamf6
Il10
Irf1
Ccl4
Tnfaip3
Rel
Nfkbia
Rgcc
Acod1
Litaf
Noct
Tnf
Rela
Il6
Hspd1
Il1r1
Il1rn
Il1b
Il1a
Tlr2
Bcl10
Nr4a3

Supplementary table related to Figure 3-11.
Gene
ENSMUSG00000000732
ENSMUSG00000000982
ENSMUSG00000004951
ENSMUSG00000011008
ENSMUSG00000015314
ENSMUSG00000016529
ENSMUSG00000018899
ENSMUSG00000018930
ENSMUSG00000019850
ENSMUSG00000020275
ENSMUSG00000021025
ENSMUSG00000022018
ENSMUSG00000022126
ENSMUSG00000022500
ENSMUSG00000023087
ENSMUSG00000024401
ENSMUSG00000024927
ENSMUSG00000025746
ENSMUSG00000025980
ENSMUSG00000026072
ENSMUSG00000026981
ENSMUSG00000027398
ENSMUSG00000027399
ENSMUSG00000027995
ENSMUSG00000028191
ENSMUSG00000028341

Basemean
1879.946841
404.881459
18265.25274
367.7904762
8.200019969
26.51114318
8354.069478
506.4697284
9466.877995
1083.526703
24691.37012
2726.351204
471.3328772
3643.467938
19075.1269
274.3510962
4893.879484
3036.369636
2345.995886
7328.016784
784.2277529
830.013287
181.8071872
2660.837425
1122.860408
505.4711915

Log2foldchange
1.504458575
2.573510088
1.877508638
-1.631015211
-3.398079137
6.728191752
2.754300098
3.636719139
5.112839587
2.66826095
2.597515239
1.582905511
3.019008041
1.317907591
1.786656712
7.476948949
0.922334974
6.195452576
0.806270299
0.955088447
4.381194878
5.071309407
3.594829976
1.430201036
1.097619431
2.774222829

Lfcse
0.063748802
0.338845122
0.027849643
0.281752415
0.877148778
1.265001615
0.038793774
0.417237964
0.050863898
0.088148803
0.0314116
0.051410787
0.697231333
0.115779666
0.049364788
0.472681179
0.047371564
1.204530641
0.056689158
0.033950889
1.052469318
0.228768058
0.420630291
0.085689834
0.07728364
0.146988934
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Stat
14.50158352
5.883248588
46.58977561
-3.730279339
-3.21277212
4.86022443
56.04765649
7.326081042
89.11703077
23.69017935
64.22835
19.50768639
3.498133153
6.373378129
24.44367268
14.59112241
7.226592197
4.661942492
3.99142102
11.04797136
3.611691869
19.63258967
7.167410525
9.921842434
6.697658539
14.92780962

Pvalue
1.18E-47
4.02E-09
0
0.000191268
0.001314605
1.17E-06
0
2.37E-13
0
4.55E-124
0
9.45E-85
0.000468527
1.85E-10
5.88E-132
3.20E-48
4.95E-13
3.13E-06
6.57E-05
2.24E-28
0.000304206
8.15E-86
7.64E-13
3.35E-23
2.12E-11
2.17E-50

Padj
1.87E-45
2.82E-07
0
0.008475666
0.049889051
6.84E-05
0
2.08E-11
0
1.16E-121
0
1.85E-82
0.019688014
1.41E-08
1.59E-129
5.12E-46
4.31E-11
0.000177085
0.003145544
2.75E-26
0.013032727
1.62E-83
6.60E-11
3.78E-21
1.71E-09
3.61E-48

Table A-5.
Symbol
Errfi1
Cxcl1
Clec4e
Ptgs2
Trib1
Nlrp3
P2ry2
Cxcl10
Amh
Ccl12
Ccl2
Sbno2
Tnfsf9
Icam1
Serpine1
Arid5a
Gch1
Ddx60
Egr1
Akap12
Thbs1
Ripk2
Prkd2
Atf4
Zc3h12a
Zfp36

Continued.
Gene
ENSMUSG00000028967
ENSMUSG00000029380
ENSMUSG00000030142
ENSMUSG00000032487
ENSMUSG00000032501
ENSMUSG00000032691
ENSMUSG00000032860
ENSMUSG00000034855
ENSMUSG00000035262
ENSMUSG00000035352
ENSMUSG00000035385
ENSMUSG00000035673
ENSMUSG00000035678
ENSMUSG00000037405
ENSMUSG00000037411
ENSMUSG00000037447
ENSMUSG00000037580
ENSMUSG00000037921
ENSMUSG00000038418
ENSMUSG00000038587
ENSMUSG00000040152
ENSMUSG00000041135
ENSMUSG00000041187
ENSMUSG00000042406
ENSMUSG00000042677
ENSMUSG00000044786

Basemean
11326.66887
28342.61911
165.0834934
32813.74795
1427.060222
233.0219436
632.2885949
51363.8536
45.20270334
349.1488707
3958.966572
8813.092372
109.0126621
29157.6081
1108.96844
4936.326917
2429.995259
1308.441645
11656.38061
43080.10233
3109.321826
1319.485889
2276.395672
5738.951968
1163.744481
18255.99707

Log2foldchange
1.690463081
9.772424871
4.894203734
4.710273664
1.343238029
2.433594939
1.058828499
4.218751018
1.864273919
4.646141295
4.742247163
1.123067615
3.228234027
4.798017735
3.22429004
2.758623668
1.416473305
-0.964823562
5.127535347
1.224603757
0.947928939
1.172687208
0.77989865
0.898136531
2.439703863
5.36220671

Lfcse
0.050563312
0.137969383
0.677775486
0.040629405
0.078522069
0.223194147
0.106080735
0.122252666
0.354205528
0.244654521
0.236644089
0.040548965
0.374449957
0.033141625
0.100707826
0.069013637
0.063911581
0.112576573
0.039328259
0.028168542
0.057249752
0.09950038
0.058322486
0.03783573
0.105298008
0.036246384
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Stat
21.96183434
66.62655643
6.365240147
101.6572518
9.72004476
8.304854597
4.513812029
29.76418539
3.625787344
16.61993117
17.58863777
13.39288485
7.072330972
127.2725067
26.25704612
31.56801704
13.08797702
-3.418327194
115.6302227
22.88381652
6.426734236
5.956632589
3.427471358
8.408362373
17.66133946
131.9361051

Pvalue
6.67E-107
0
1.95E-10
0
2.48E-22
9.99E-17
6.37E-06
1.14E-194
0.000288082
5.00E-62
3.01E-69
6.65E-41
1.52E-12
0
5.94E-152
1.01E-218
3.86E-39
0.000630073
0
6.73E-116
1.30E-10
2.57E-09
0.000609231
4.16E-17
8.32E-70
0

Padj
1.49E-104
0
1.48E-08
0
2.77E-20
9.62E-15
0.000346566
3.67E-192
0.012366119
8.84E-60
5.55E-67
9.48E-39
1.30E-10
0
1.76E-149
3.59E-216
5.39E-37
0.025736786
0
1.61E-113
1.00E-08
1.84E-07
0.024931852
4.05E-15
1.56E-67
0

Table A-5.
Symbol
Trim16
C5ar1
Trex1
Cd14
Cx3cr1
Jun
Junb
Bcl3
Nod2
Cebpg
Cebpb
Cxcl2
Osm
Jund
Gbp5

Continued.
Gene
ENSMUSG00000047821
ENSMUSG00000049130
ENSMUSG00000049734
ENSMUSG00000051439
ENSMUSG00000052336
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000053175
ENSMUSG00000055994
ENSMUSG00000056216
ENSMUSG00000056501
ENSMUSG00000058427
ENSMUSG00000058755
ENSMUSG00000071076
ENSMUSG00000105504

Basemean
1325.781937
233.3220744
1410.032733
7579.922493
149.401536
10484.16994
15095.43776
1716.137156
1137.687625
2934.115846
5094.091349
8389.878604
23.80602464
7427.17751
24611.98318

Log2foldchange
0.85961342
1.607206308
1.050249214
4.130935146
-1.236052231
3.415445587
4.779297401
1.882687321
1.744765935
0.798737439
3.016514087
9.280584959
2.740166002
1.248338655
1.105360729

Lfcse
0.064079163
0.173967068
0.086420365
0.095928659
0.170012864
0.037984906
0.040769667
0.115566107
0.085448101
0.058515273
0.055001565
0.283354639
0.661382245
0.037894183
0.055289156

114

Stat
4.363562286
5.904602064
5.441416647
37.01641584
-3.85883876
74.64663962
103.0005316
11.27222637
13.63126769
3.738125601
44.29899535
30.7056379
3.266138484
17.63697232
9.502057296

Pvalue
1.28E-05
3.53E-09
5.29E-08
6.23E-300
0.000113927
0
0
1.80E-29
2.61E-42
0.000185397
0
4.79E-207
0.001090249
1.28E-69
2.06E-21

Padj
0.000668294
2.49E-07
3.50E-06
2.49E-297
0.005272131
0
0
2.24E-27
3.84E-40
0.008232167
0
1.64E-204
0.042401801
2.38E-67
2.27E-19

Table A-6.

Supplementary table related to Figure 3-13A.

Symbol

Gene

Klf4
Rgcc
Adamts1
Xdh
Creb3l1
Angpt4
Sema4a
Adgrb2
Adgrb1
Cxcl10
Tgfb2
Abcc8
Klf2

ENSMUSG00000003032
ENSMUSG00000022018
ENSMUSG00000022893
ENSMUSG00000024066
ENSMUSG00000027230
ENSMUSG00000027460
ENSMUSG00000028064
ENSMUSG00000028782
ENSMUSG00000034730
ENSMUSG00000034855
ENSMUSG00000039239
ENSMUSG00000040136
ENSMUSG00000055148

Basemean
5628.479158
2726.351204
16433.79349
10150.73315
311.2062805
19.28326026
548.2476075
2309.912385
5634.586257
51363.8536
1720.669867
298.3627786
17486.56426

Log2foldchange
1.561054452
1.391072291
1.898210089
0.801509034
-1.053438381
-2.804211367
1.038197397
1.187971288
1.034612651
1.080808763
-1.078693121
1.441290513
1.787370514

Lfcse
0.039249817
0.051384252
0.032084745
0.044141597
0.14073789
0.528323619
0.105836351
0.086566445
0.049206819
0.142671141
0.063313852
0.214336351
0.025624093
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Stat
24.99513455
15.78445258
41.08525936
5.018147302
-3.36397243
-4.209941194
4.329300767
7.023174946
9.238814081
3.510231704
-7.876524781
4.018406154
47.11856527

Pvalue
6.91E-138
3.98E-56
0
5.22E-07
0.000768292
2.55E-05
1.50E-05
2.17E-12
2.49E-20
0.000447716
3.37E-15
5.86E-05
0

Padj
5.73E-135
1.76E-53
0
4.14E-05
0.036555603
0.001619911
0.000975637
2.81E-10
5.22E-18
0.022690504
5.21E-13
0.003511016
0

Table A-7.
to PBS.
Symbol
Alox12
Tnf
Ptgs2
Manf
P2ry2
Dusp5
Icam1
Gch1
Kcna5
Per2
Kdr
Gpx1

Supplementary table related to Figure 3-13B listing pairwise comparison statistics in LPS 30 minutes compared

Gene
ENSMUSG00000000320
ENSMUSG00000024401
ENSMUSG00000032487
ENSMUSG00000032575
ENSMUSG00000032860
ENSMUSG00000034765
ENSMUSG00000037405
ENSMUSG00000037580
ENSMUSG00000045534
ENSMUSG00000055866
ENSMUSG00000062960
ENSMUSG00000063856

Basemean
317.3473577
274.3510962
32813.74795
2123.97003
632.2885949
313.5667066
29157.6081
2429.995259
1146.58785
1530.504748
4464.77845
7074.013933

Log2foldchange
-1.238545462
7.476948949
4.710273664
0.80372198
1.058828499
3.641002673
4.798017735
1.416473305
1.817064797
2.58010422
-1.019209275
1.513798805

Lfcse
0.126138344
0.472681179
0.040629405
0.058282624
0.106080735
0.153367445
0.033141625
0.063911581
0.086049858
0.074760952
0.036781665
0.0362497
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Stat
-5.22081898
14.59112241
101.6572518
3.838570858
4.513812029
19.95862072
127.2725067
13.08797702
14.37613987
26.75332718
-11.94098391
25.76018028

Pvalue
1.78E-07
3.20E-48
0
0.000123753
6.37E-06
1.26E-88
0
3.86E-39
7.31E-47
1.13E-157
7.24E-33
2.48E-146

Padj
1.13E-05
5.12E-46
0
0.005678894
0.000346566
2.59E-86
0
5.39E-37
1.14E-44
3.39E-155
9.23E-31
7.06E-144

Table A-8.
PBS.
Symbol
Rock2
Akap11
Cldn1
Tnf
Il1b
Abcb1b
Add1
Tnfrsf1a
Msn
Cdh5
Myd88
Icam1
Ppp1r16b
F11r
Cldn5
Sox18
Rap2c
Ezr
Rap1b
Rapgef2
S1pr3
Afdn
Pde2a

Supplementary table related to Figure 3-14A listing pairwise comparison statistics in LPS 4 hours compared to

Gene
ENSMUSG00000020580
ENSMUSG00000022016
ENSMUSG00000022512
ENSMUSG00000024401
ENSMUSG00000027398
ENSMUSG00000028970
ENSMUSG00000029106
ENSMUSG00000030341
ENSMUSG00000031207
ENSMUSG00000031871
ENSMUSG00000032508
ENSMUSG00000037405
ENSMUSG00000037754
ENSMUSG00000038235
ENSMUSG00000041378
ENSMUSG00000046470
ENSMUSG00000050029
ENSMUSG00000052397
ENSMUSG00000052681
ENSMUSG00000062232
ENSMUSG00000067586
ENSMUSG00000068036
ENSMUSG00000110195

Basemean
3758.17721
2627.730733
864.6534226
274.3510962
830.013287
328.3272325
3748.931222
3178.189208
13388.79528
17510.59564
2131.672384
29157.6081
1373.950257
4517.130126
30428.70436
5602.589436
696.1819687
4317.461626
5501.669084
3063.862558
1641.50632
3429.291756
6427.670728

Log2foldchange
1.036686543
1.613012618
1.780373756
7.705633286
7.772446081
2.583478401
-1.140493974
1.752788543
1.621256529
1.939112582
3.448350873
5.737082798
-2.046347194
1.658245782
-2.33273169
-4.392841692
1.09626283
1.261849832
1.614504233
0.969347635
1.027696018
-0.916680434
-1.75261646
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Lfcse
0.049498154
0.060526514
0.074041812
0.47324616
0.226232124
0.266590107
0.07114637
0.041417602
0.027567151
0.023559715
0.052121016
0.033101335
0.084805321
0.0501587
0.024128197
0.062353899
0.089976966
0.041061805
0.036870195
0.078068148
0.061989425
0.056710912
0.090581079

Stat
9.226334822
17.06710911
16.21210659
15.05692784
31.79232891
7.515201601
-7.87804038
28.31618665
37.77164121
57.68798907
55.0325201
155.7968234
-17.29074508
21.49668523
-72.6424649
-61.1484084
5.737722147
16.60545206
28.05800834
4.987279028
7.222135334
-5.936783953
-12.94549011

Pvalue
2.80E-20
2.61E-65
4.14E-59
3.11E-51
8.26E-222
5.68E-14
3.33E-15
2.18E-176
0
0
0
0
5.52E-67
1.67E-102
0
0
9.60E-09
6.36E-62
3.19E-173
6.12E-07
5.12E-13
2.91E-09
2.49E-38

Padj
3.67E-19
6.31E-64
9.42E-58
6.58E-50
4.32E-220
6.17E-13
3.77E-14
9.59E-175
0
0
0
0
1.35E-65
5.30E-101
0
0
8.35E-08
1.49E-60
1.39E-171
4.74E-06
5.38E-12
2.62E-08
4.49E-37

Table A-9.
Supplementary table related to Figure 3-23 listing pairwise comparison statistics in CECs LPS 30 minutes
compared to CECs PBS.
Symbol
Ier3
Fosb
Fos
Nr4a1
Dusp1
Atf3
Egr3
Egr1
Jun
Junb
Ier2
Hspa1a

Gene
ENSMUSG00000003541
ENSMUSG00000003545
ENSMUSG00000021250
ENSMUSG00000023034
ENSMUSG00000024190
ENSMUSG00000026628
ENSMUSG00000033730
ENSMUSG00000038418
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000053560
ENSMUSG00000091971

Basemean
8135.428722
219.4164628
5687.064247
5131.201155
16564.87115
4560.245227
570.0468307
12809.86023
11671.66241
13748.22188
8088.842212
2661.949302

Log2foldchange
2.336973656
2.309806057
4.209372136
1.930970851
2.154312343
1.799667051
2.526006567
5.238246897
1.265590318
3.973721717
2.331138913
3.794901738

Lfcse
0.292535323
0.587907419
0.303381489
0.570182562
0.36404657
0.369939016
0.729129483
0.386420953
0.258361775
0.188333679
0.249676643
0.762873947
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Stat
7.988688796
3.928860193
13.8748483
3.386583488
5.917683398
4.864766827
3.464414243
13.55580451
4.898519978
21.09936867
9.336631906
4.974480718

Pvalue
1.36E-15
8.53E-05
9.00E-44
0.000707687
3.27E-09
1.15E-06
0.000531388
7.32E-42
9.66E-07
8.06E-99
9.94E-21
6.54E-07

Padj
1.91E-12
0.009096738
3.03E-40
0.039331537
2.04E-06
0.000321621
0.0329063
2.05E-38
0.000285279
1.36E-94
2.09E-17
0.000216023

Table A-10. Supplementary table related to Figure 3-23 listing pairwise comparison statistics in CECs LPS 1 hour compared
to CECs PBS.
Symbol
Ier3
Fosb
Fos
Nr4a1
Dusp1
Atf3
Egr3
Egr1
Jun
Junb
Ier2
Hspa1a

Gene
ENSMUSG00000003541
ENSMUSG00000003545
ENSMUSG00000021250
ENSMUSG00000023034
ENSMUSG00000024190
ENSMUSG00000026628
ENSMUSG00000033730
ENSMUSG00000038418
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000053560
ENSMUSG00000091971

Basemean
8135.428722
219.4164628
5687.064247
5131.201155
16564.87115
4560.245227
570.0468307
12809.86023
11671.66241
13748.22188
8088.842212
2661.949302

Log2foldchange
4.316206651
4.365501174
4.69781694
3.280229
2.388631018
3.48503994
4.826944369
5.998727078
0.898878533
5.051029738
3.059192794
2.911758218

Lfcse
0.292386187
0.585844574
0.303330732
0.570143371
0.364042368
0.369720016
0.728558975
0.386402528
0.258386861
0.188256341
0.249633889
0.762907353

Stat
14.76200603
7.451637122
15.48744142
5.753340597
6.561409416
9.426159763
6.625331012
15.52455441
3.478808985
26.83059556
12.25471752
3.816660315

Pvalue
2.58E-49
9.22E-14
4.22E-54
8.75E-09
5.33E-11
4.25E-21
3.46E-11
2.37E-54
0.000503647
1.42E-158
1.59E-34
0.00013527

Padj
3.10E-46
2.25E-11
5.46E-51
1.23E-06
9.97E-09
1.71E-18
6.63E-09
3.32E-51
0.017309026
2.39E-154
1.33E-31
0.006355915

Table A-11. Supplementary table related to Figure 3-23 listing pairwise comparison statistics in microglia LPS 1 hour
compared to microglia PBS.
Symbol
Ier3
Dusp1

Gene
ENSMUSG00000003541
ENSMUSG00000024190

Basemean
8135.428722
16564.87115

Log2foldchange
1.167898781
1.816826788

Lfcse
0.303572978
0.364844929

119

Stat
3.847176353
4.979723285

Pvalue
0.000119487
6.37E-07

Padj
0.040820259
0.000493788

Table A-12. Supplementary table related to Figure 3-23 listing pairwise comparison statistics in CECs LPS 2 hours
compared to CECs PBS.
Symbol
Ier3
Fosb
Fos
Nr4a1
Atf3
Egr3
Egr1
Jun
Junb
Ier2

Gene
ENSMUSG00000003541
ENSMUSG00000003545
ENSMUSG00000021250
ENSMUSG00000023034
ENSMUSG00000026628
ENSMUSG00000033730
ENSMUSG00000038418
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000053560

Basemean
8135.428722
219.4164628
5687.064247
5131.201155
4560.245227
570.0468307
12809.86023
11671.66241
13748.22188
8088.842212

Log2foldchange
4.683655051
3.48459486
5.738916731
1.419692743
4.823369651
2.727501882
5.371384782
0.964812394
5.070908527
2.717994436

Lfcse
0.292398145
0.587061097
0.303307107
0.570257961
0.369686364
0.729372093
0.386438245
0.258458147
0.188294284
0.249694978

120

Stat
16.01807373
5.93565964
18.92114163
2.489562337
13.04719385
3.739520483
13.89972358
3.732954076
26.93076192
10.88525874

Pvalue
9.56E-58
2.93E-09
7.64E-80
0.012790049
6.59E-39
0.000184372
6.36E-44
0.000189247
9.59E-160
1.36E-27

Padj
2.00E-55
5.29E-08
3.15E-77
0.047983168
7.01E-37
0.001317063
8.29E-42
0.001348288
2.08E-156
9.33E-26

Table A-13. Supplementary table related to Figure 3-23 listing pairwise comparison statistics in microglia LPS 2 hours
compared to microglia PBS.
Symbol
Ier3
Fos
Nr4a1
Dusp1
Egr3
Egr1
Junb
Ier2
Hspa1a

Gene
ENSMUSG00000003541
ENSMUSG00000021250
ENSMUSG00000023034
ENSMUSG00000024190
ENSMUSG00000033730
ENSMUSG00000038418
ENSMUSG00000052837
ENSMUSG00000053560
ENSMUSG00000091971

Basemean
8135.428722
5687.064247
5131.201155
16564.87115
570.0468307
12809.86023
13748.22188
8088.842212
2661.949302

Log2foldchange
5.861828001
2.475565632
3.128970741
4.207821414
2.384895347
4.119458749
2.84917422
4.315333951
-2.675590888

Lfcse
0.300134497
0.302216671
0.577905919
0.364691633
0.770700634
0.385892396
0.187051031
0.251993964
0.765105934

121

Stat
19.53067064
8.191360284
5.41432548
11.53802564
3.094450997
10.67514882
15.23206903
17.12475128
-3.497020177

Pvalue
6.02E-85
2.58E-16
6.15E-08
8.49E-31
0.001971775
1.33E-26
2.17E-52
9.70E-66
0.000470486

Padj
4.62E-81
4.50E-14
4.18E-06
3.17E-28
0.046815922
4.00E-24
2.56E-49
2.13E-62
0.014066897

Table A-14.
Symbol
Tnfaip3
Nfkbia
Litaf
Tnf
Cxcl1
Arid5a
Gch1
Zfp36
Jun
Junb
Cxcl2
Irak2

Supplementary table related to Figure 3-24.
Gene

ENSMUSG00000019850
ENSMUSG00000021025
ENSMUSG00000022500
ENSMUSG00000024401
ENSMUSG00000029380
ENSMUSG00000037447
ENSMUSG00000037580
ENSMUSG00000044786
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000058427
ENSMUSG00000060477

Basemean
7910.386742
27835.28986
7770.491065
1042.572106
8769.124715
6760.818824
3923.860293
17516.75061
11671.66241
13748.22188
926.0697058
4961.489113

Log2foldchange
2.381939944
1.186108274
1.5357449
5.377209529
5.911435088
0.781413651
0.943525179
3.890691681
1.265590318
3.973721717
5.359533649
1.055770215

Lfcse
0.40323561
0.23952242
0.206962037
0.692324133
0.366120477
0.221836169
0.245093601
0.190475043
0.258361775
0.188333679
0.579689326
0.1643567

122

Stat
5.907067442
4.951971823
7.420418375
7.76689599
16.14614711
3.522480819
3.849652431
20.42625441
4.898519978
21.09936867
9.245527583
6.423651819

Pvalue
3.48E-09
7.35E-07
1.17E-13
8.04E-15
1.21E-58
0.000427528
0.000118286
9.77E-93
9.66E-07
8.06E-99
2.34E-20
1.33E-10

Padj
2.09E-06
0.000237807
1.31E-10
1.04E-11
6.79E-55
0.028569727
0.012072295
8.23E-89
0.000285279
1.36E-94
4.38E-17
1.12E-07

Table A-15.
Symbol
Tgfb1
Relb
Bcr
Hyal2
Irf1
Tnfaip3
Rel
Nfkbia
Edn1
Clu
Litaf
Noct
Tnf
Rela
Nfkb2
Alpk1
Bcl10
Nr4a3
Errfi1
Prkcz
Cxcl1
Cx3cl1
Birc3
Ptgs2
P2ry2
Cxcl10

Supplementary table related to Figure 3-25A.
Gene

ENSMUSG00000002603
ENSMUSG00000002983
ENSMUSG00000009681
ENSMUSG00000010047
ENSMUSG00000018899
ENSMUSG00000019850
ENSMUSG00000020275
ENSMUSG00000021025
ENSMUSG00000021367
ENSMUSG00000022037
ENSMUSG00000022500
ENSMUSG00000023087
ENSMUSG00000024401
ENSMUSG00000024927
ENSMUSG00000025225
ENSMUSG00000028028
ENSMUSG00000028191
ENSMUSG00000028341
ENSMUSG00000028967
ENSMUSG00000029053
ENSMUSG00000029380
ENSMUSG00000031778
ENSMUSG00000032000
ENSMUSG00000032487
ENSMUSG00000032860
ENSMUSG00000034855

Basemean
2507.480189
1340.526405
1844.242677
1985.612833
15271.61072
7910.386742
1237.461989
27835.28986
2259.61847
3821.713187
7770.491065
4679.07607
1042.572106
6819.144291
1853.369785
128.4493761
1749.916425
96.09023724
2397.684275
70.47244279
8769.124715
7029.169566
2369.327228
4963.684051
1119.019686
27643.5159

Log2foldchange
1.059087022
0.854292574
1.60849972
0.586900663
2.809774987
4.824742281
2.927779886
2.13622235
1.493533582
-0.980824386
2.208903877
2.792337948
7.856960417
0.99936955
1.153515503
2.444182093
1.400044019
3.794400712
2.524757026
-1.708238858
9.391318365
1.334806587
1.563963041
3.265914323
1.303398894
3.678949719

Lfcse
0.13798266
0.21260686
0.416896267
0.131349376
0.15375579
0.402928175
0.337268209
0.239496186
0.3083393
0.316666189
0.20669228
0.240463924
0.686295555
0.137605151
0.253946034
0.742308775
0.103262245
0.85919269
0.305552109
0.530200938
0.365634199
0.392256534
0.280805923
0.619988566
0.352183459
0.505030987

123

Stat
7.675508057
4.018179717
3.858273264
4.468240951
18.27427114
11.97419933
8.680865291
8.919650804
4.843798966
-3.097344841
10.68692005
11.61229469
11.44836267
7.262588232
4.542364704
3.292675738
13.55814043
4.41623952
8.262934386
-3.221870683
25.68501084
3.402891911
5.569551464
5.267700893
3.700908885
7.284601965

Pvalue
1.65E-14
5.86E-05
0.000114191
7.89E-06
1.33E-74
4.85E-33
3.93E-18
4.68E-19
1.27E-06
0.001952626
1.17E-26
3.57E-31
2.40E-30
3.80E-13
5.56E-06
0.000992389
7.09E-42
1.00E-05
1.42E-16
0.001273566
1.72E-145
0.000666767
2.55E-08
1.38E-07
0.000214829
3.23E-13

Padj
4.34E-12
0.003217123
0.005639224
0.000606436
3.72E-71
3.71E-30
1.30E-15
1.68E-16
0.000112899
0.046575381
6.37E-24
2.50E-28
1.49E-27
8.64E-11
0.000437735
0.028373215
7.96E-39
0.000758425
4.27E-14
0.034260147
9.65E-142
0.021428146
3.33E-06
1.61E-05
0.009156322
7.44E-11

Table A-15.
Symbol
Sbno2
Nfkbid
Icam1
Serpine1
Arid5a
Gch1
Egr1
Akap12
Ripk2
Atf4
Zc3h12a
Zfp36
Tifa
Trex1
Jun
Junb
Bcl3
Nod2
Cxcl2
Cxcl11
Irak2
Jund

Continued.
Gene

ENSMUSG00000035673
ENSMUSG00000036931
ENSMUSG00000037405
ENSMUSG00000037411
ENSMUSG00000037447
ENSMUSG00000037580
ENSMUSG00000038418
ENSMUSG00000038587
ENSMUSG00000041135
ENSMUSG00000042406
ENSMUSG00000042677
ENSMUSG00000044786
ENSMUSG00000046688
ENSMUSG00000049734
ENSMUSG00000052684
ENSMUSG00000052837
ENSMUSG00000053175
ENSMUSG00000055994
ENSMUSG00000058427
ENSMUSG00000060183
ENSMUSG00000060477
ENSMUSG00000071076

Basemean
6547.703709
581.4950379
43731.10471
66.32557586
6760.818824
3923.860293
12809.86023
18875.22354
1062.526998
1958.857838
489.2115939
17516.75061
2287.128138
2840.854999
11671.66241
13748.22188
1950.996273
152.6489868
926.0697058
1006.579109
4961.489113
3952.106918

Log2foldchange
1.650526882
7.537214177
4.686395468
4.823362092
1.887416993
1.048962695
5.998727078
1.141460079
1.212675819
1.026950851
3.799972203
5.004977939
2.084513907
2.314923096
0.898878533
5.051029738
1.98766244
2.602853473
9.34911204
2.717911833
1.396951018
1.083051938

Lfcse
0.211230389
0.482380838
0.234291155
0.950030401
0.221554406
0.245067139
0.386402528
0.360619148
0.276350286
0.14688433
0.299478976
0.190426562
0.256859329
0.192800518
0.258386861
0.188256341
0.277745028
0.535978652
0.575419051
0.583923996
0.164213675
0.206580068

124

Stat
7.813870378
15.62502817
20.00244297
5.077060784
8.518977465
4.280307431
15.52455441
3.165278622
4.388183701
6.991561683
12.6886109
26.28298221
8.11539108
12.00683029
3.478808985
26.83059556
7.15642851
4.856263326
16.24748438
4.654564382
8.506910402
5.242770754

Pvalue
5.55E-15
4.92E-55
5.24E-89
3.83E-07
1.61E-17
1.87E-05
2.37E-54
0.001549345
1.14E-05
2.72E-12
6.84E-37
3.00E-152
4.84E-16
3.27E-33
0.000503647
1.42E-158
8.28E-13
1.20E-06
2.33E-59
3.25E-06
1.79E-17
1.58E-07

Padj
1.51E-12
7.53E-52
1.77E-85
3.98E-05
5.11E-15
0.00128809
3.32E-51
0.039955546
0.000836884
5.58E-10
6.40E-34
2.53E-148
1.38E-13
2.62E-30
0.017309026
2.39E-154
1.81E-10
0.000107723
4.35E-56
0.000269329
5.57E-15
1.79E-05

Table A-16. Supplementary table related to Figure 3-25B listing pairwise comparison statistics in microglia LPS 1 hour
compared to microglia PBS.
Symbol
Nfkbia
Tnf
Il1b
Cxcl1
Ptgs2
Cxcl10
Cxcl2

Gene
ENSMUSG00000021025
ENSMUSG00000024401
ENSMUSG00000027398
ENSMUSG00000029380
ENSMUSG00000032487
ENSMUSG00000034855
ENSMUSG00000058427

Basemean
27835.28986
1042.572106
2717.403984
8769.124715
4963.684051
27643.5159
926.0697058

Log2foldchange
1.572368413
2.718076665
2.848321268
7.405799174
4.382767045
2.247146779
4.895931982

Lfcse
0.240371502
0.439467669
0.571237158
1.07762474
0.862765525
0.503956425
0.697472926

125

Stat
6.541409457
6.184929766
4.986232479
6.872335885
5.079905162
4.459010077
7.01952979

Pvalue
6.09E-11
6.21E-10
6.16E-07
6.32E-12
3.78E-07
8.23E-06
2.23E-12

Padj
1.55E-07
1.39E-06
0.000493788
1.88E-08
0.000320728
0.005439257
9.22E-09

Table A-17.
Symbol
Hpn
Pmp22
Irf1
Tnfaip3
Nf1
Dusp1
Tnf
Ptprc
Mar7
Pde3b
Plxnb3
Dusp5
C1qa
C1qc
C1qb
Nfkbid
Icam1
Gch1
Ctss
Rnd1

Supplementary table related to Figure 3-29.
Gene

ENSMUSG00000001249
ENSMUSG00000018217
ENSMUSG00000018899
ENSMUSG00000019850
ENSMUSG00000020716
ENSMUSG00000024190
ENSMUSG00000024401
ENSMUSG00000026395
ENSMUSG00000026977
ENSMUSG00000030671
ENSMUSG00000031385
ENSMUSG00000034765
ENSMUSG00000036887
ENSMUSG00000036896
ENSMUSG00000036905
ENSMUSG00000036931
ENSMUSG00000037405
ENSMUSG00000037580
ENSMUSG00000038642
ENSMUSG00000054855

Basemean
89.13264462
7785.551826
15271.61072
7910.386742
236.7811338
16564.87115
1042.572106
3057.618869
1061.994783
5281.451887
196.9264164
293.8495755
35905.89582
51400.31892
64973.93876
581.4950379
43731.10471
3923.860293
59580.50645
4907.485517

Log2foldchange
-4.926243148
0.614641195
0.829160099
2.381939944
1.681174979
2.154312343
5.377209529
1.890922999
-0.666796392
2.183187118
-4.758352495
2.991254662
1.254550087
1.152980796
0.923717915
4.794383885
0.926677201
0.943525179
1.284049935
1.607720828

Lfcse
1.298193429
0.134032113
0.154150522
0.40323561
0.446483956
0.36404657
0.692324133
0.525068059
0.168482753
0.580621882
1.245197044
0.457487969
0.229437985
0.311178398
0.276973229
0.485665253
0.234798733
0.245093601
0.295781457
0.391120644

126

Stat
-3.794691175
4.585775625
5.378899063
5.907067442
3.765364818
5.917683398
7.76689599
3.601291235
-3.957653719
3.760084123
-3.821365076
6.5384335
5.467926723
3.705208338
3.335044036
9.871786905
3.946687403
3.849652431
4.34121174
4.110549651

Pvalue
0.000147827
4.52E-06
7.49E-08
3.48E-09
0.000166306
3.27E-09
8.04E-15
0.000316641
7.57E-05
0.000169856
0.000132715
6.22E-11
4.55E-08
0.000211217
0.000852859
5.52E-23
7.92E-05
0.000118286
1.42E-05
3.95E-05

Padj
0.013988991
0.001062378
3.16E-05
2.09E-06
0.015199055
2.04E-06
1.04E-11
0.024117919
0.008385608
0.015296144
0.013303101
5.51E-08
2.07E-05
0.017826638
0.044881701
1.33E-19
0.008664935
0.012072295
0.002386213
0.005152758

Table A-18. Supplementary table related to supplementary Figure 3-30A listing pairwise comparison statistics in CECs LPS
2 hours compared to CECs PBS.
Symbol
Mapk7
Angptl4
Hipk1
Gata2
Nfe2l2
H2-M3
Cd40
Tnfaip3
Xbp1
Rock2
Marveld2
Rgcc
Rapgef3
Rock1
Tnf
Tjp2
Abl2
Il1b
Tnfrsf1a
Pak4
Msn
Ikbkb
Myd88
Ccl12
Icam1

Gene

Basemean

ENSMUSG00000001034
ENSMUSG00000002289
ENSMUSG00000008730
ENSMUSG00000015053
ENSMUSG00000015839
ENSMUSG00000016206
ENSMUSG00000017652
ENSMUSG00000019850
ENSMUSG00000020484
ENSMUSG00000020580
ENSMUSG00000021636
ENSMUSG00000022018
ENSMUSG00000022469
ENSMUSG00000024290
ENSMUSG00000024401
ENSMUSG00000024812
ENSMUSG00000026596
ENSMUSG00000027398
ENSMUSG00000030341
ENSMUSG00000030602
ENSMUSG00000031207
ENSMUSG00000031537
ENSMUSG00000032508
ENSMUSG00000035352
ENSMUSG00000037405

580.6858303
765.7255422
1225.084767
2286.950443
4150.173826
820.2550881
984.1722645
7910.386742
6690.955555
2519.091824
237.6618284
2797.369179
2730.359467
1699.135833
1042.572106
2091.690126
411.0228656
2717.403984
3278.782048
675.9973474
15819.01783
1880.504538
2807.815602
2596.325135
43731.10471

Log2foldchange
-1.612498273
1.950641689
0.925725775
-2.047916162
1.43381944
1.153458563
3.096348537
5.714406435
1.739368133
0.74546316
0.901914598
1.784736267
1.553971258
0.727506264
7.749220036
0.783721692
2.110738509
4.676412775
1.129434837
0.971402377
0.779151526
0.79292622
4.488791382
5.590246843
7.609493408

Lfcse
0.34426695
0.463477179
0.268436379
0.227095151
0.114516219
0.232326236
0.427209051
0.402919648
0.121218698
0.217128206
0.306460949
0.307889427
0.31777902
0.135639106
0.687219918
0.205967594
0.448870718
0.619715314
0.134648874
0.231837366
0.221829448
0.213689362
0.207131708
0.548888767
0.234260715
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Stat
-4.683860217
4.208711406
3.448585395
-9.017877086
12.520667
4.964822679
7.247853308
14.18249636
14.34900856
3.433285677
2.943000084
5.796679296
4.890100232
5.363543632
11.2761866
3.805072819
4.702330593
7.546066185
8.388000576
4.190016456
3.512389954
3.710649014
21.67119379
10.1846625
32.48301114

Pvalue
2.82E-06
2.57E-05
0.000563531
1.92E-19
5.75E-36
6.88E-07
4.23E-13
1.18E-45
1.08E-46
0.000596313
0.003250483
6.76E-09
1.01E-06
8.16E-08
1.72E-29
0.000141762
2.57E-06
4.49E-14
4.94E-17
2.79E-05
0.000444096
0.000206729
3.84E-104
2.32E-24
1.85E-231

Padj
3.13E-05
0.000230882
0.003513914
8.73E-18
5.70E-34
8.60E-06
1.17E-11
1.67E-43
1.62E-44
0.003689144
0.0155795
1.16E-07
1.22E-05
1.20E-06
1.32E-27
0.001050557
2.89E-05
1.36E-12
1.93E-15
0.000248817
0.002850136
0.001457861
2.89E-101
1.35E-22
1.07E-227

Table A-18.

Continued.

Symbol

Gene

Basemean

Serpine1
F11r
Rapgef1
Thbs1
Cldn5
Sox18
Ndnf
Rap1b
Gper1
Tnip2
Kdr
Bmpr2
Afdn
Myadm

ENSMUSG00000037411
ENSMUSG00000038235
ENSMUSG00000039844
ENSMUSG00000040152
ENSMUSG00000041378
ENSMUSG00000046470
ENSMUSG00000049001
ENSMUSG00000052681
ENSMUSG00000053647
ENSMUSG00000059866
ENSMUSG00000062960
ENSMUSG00000067336
ENSMUSG00000068036
ENSMUSG00000068566

66.32557586
13419.00546
1534.432818
744.4556348
25242.63569
4160.119484
1523.065355
11441.10811
548.0492641
721.1379561
8316.589914
1631.045543
1258.247632
5069.47159

Log2foldchange
6.90205129
0.688231479
1.293862028
3.642389916
-1.246527436
-2.183144597
-2.597501481
1.307163531
-1.958672915
1.007795425
-1.353880163
0.815998616
0.947656401
0.695229586

Lfcse
0.945622916
0.085773999
0.203064389
0.502365407
0.255827362
0.300484856
0.510313148
0.095296097
0.315904786
0.194177756
0.316855488
0.199240505
0.280885892
0.227192237
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Stat
7.29894673
8.023777476
6.37168357
7.250479165
-4.872533681
-7.265406401
-5.090014807
13.7168632
-6.200200191
5.190066281
-4.27286322
4.095545808
3.373812739
3.060093934

Pvalue
2.90E-13
1.03E-15
1.87E-10
4.15E-13
1.10E-06
3.72E-13
3.58E-07
8.05E-43
5.64E-10
2.10E-07
1.93E-05
4.21E-05
0.000741348
0.002212676

Padj
8.15E-12
3.58E-14
3.88E-09
1.15E-11
1.33E-05
1.03E-11
4.74E-06
1.00E-40
1.10E-08
2.90E-06
0.000178788
0.000358371
0.004451424
0.011301918
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